WO2018195522A1 - Arid5b overexpression in inflammatory diseases - Google Patents
Arid5b overexpression in inflammatory diseases Download PDFInfo
- Publication number
- WO2018195522A1 WO2018195522A1 PCT/US2018/028747 US2018028747W WO2018195522A1 WO 2018195522 A1 WO2018195522 A1 WO 2018195522A1 US 2018028747 W US2018028747 W US 2018028747W WO 2018195522 A1 WO2018195522 A1 WO 2018195522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- arid5b
- subject
- expression
- methylation
- cpg
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 32
- 230000002018 overexpression Effects 0.000 title abstract description 4
- 230000014509 gene expression Effects 0.000 claims abstract description 161
- 102100030835 AT-rich interactive domain-containing protein 5B Human genes 0.000 claims abstract description 157
- 101000792947 Homo sapiens AT-rich interactive domain-containing protein 5B Proteins 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 95
- 230000011987 methylation Effects 0.000 claims abstract description 78
- 238000007069 methylation reaction Methods 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 108091029430 CpG site Proteins 0.000 claims abstract description 29
- 101150106318 Arid5b gene Proteins 0.000 claims abstract description 19
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 55
- 201000001320 Atherosclerosis Diseases 0.000 claims description 44
- 150000007523 nucleic acids Chemical group 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- 108020004459 Small interfering RNA Proteins 0.000 claims description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims description 17
- 230000030279 gene silencing Effects 0.000 claims description 14
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 10
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 238000012226 gene silencing method Methods 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims description 4
- 239000002924 silencing RNA Substances 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 84
- 108020004999 messenger RNA Proteins 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 49
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 43
- 239000011575 calcium Substances 0.000 description 43
- 229910052791 calcium Inorganic materials 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 210000001616 monocyte Anatomy 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 239000000523 sample Substances 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 32
- 230000009368 gene silencing by RNA Effects 0.000 description 32
- 102000039446 nucleic acids Human genes 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 32
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 239000003814 drug Substances 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 20
- 230000007067 DNA methylation Effects 0.000 description 19
- 238000003556 assay Methods 0.000 description 17
- 241000282414 Homo sapiens Species 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- -1 poly(orthoesters) Polymers 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 239000002679 microRNA Substances 0.000 description 15
- 101710163270 Nuclease Proteins 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 108091070501 miRNA Proteins 0.000 description 12
- 108091033409 CRISPR Proteins 0.000 description 11
- 230000001404 mediated effect Effects 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000002493 microarray Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108010077544 Chromatin Proteins 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 8
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 8
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 8
- 210000003483 chromatin Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 108010033040 Histones Proteins 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000028709 inflammatory response Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- 238000010459 TALEN Methods 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical group O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012417 linear regression Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000000391 smoking effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000012384 transportation and delivery Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 5
- 101000968916 Homo sapiens Methylsterol monooxygenase 1 Proteins 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102100021091 Methylsterol monooxygenase 1 Human genes 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 201000009104 prediabetes syndrome Diseases 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 238000012175 pyrosequencing Methods 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100033337 PDZ and LIM domain protein 7 Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008777 canonical pathway Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000019504 cigarettes Nutrition 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000005782 double-strand break Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 101150059521 AHRR gene Proteins 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 102100026789 Aryl hydrocarbon receptor repressor Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 108020005004 Guide RNA Proteins 0.000 description 3
- 101001134647 Homo sapiens PDZ and LIM domain protein 7 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000003012 network analysis Methods 0.000 description 3
- 108091027963 non-coding RNA Proteins 0.000 description 3
- 102000042567 non-coding RNA Human genes 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002974 pharmacogenomic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102100027328 2-hydroxyacyl-CoA lyase 2 Human genes 0.000 description 2
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 2
- 240000005020 Acaciella glauca Species 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 101001009238 Homo sapiens 2-hydroxyacyl-CoA lyase 2 Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000740762 Homo sapiens Voltage-dependent calcium channel subunit alpha-2/delta-3 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
- 102100026395 Lysine-specific demethylase PHF2 Human genes 0.000 description 2
- 101710128369 Lysine-specific demethylase phf2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 2
- PGAUJQOPTMSERF-QWQRBHLCSA-N Methenolone acetate Chemical compound C([C@@H]1CC2)C(=O)C=C(C)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)C)[C@@]2(C)CC1 PGAUJQOPTMSERF-QWQRBHLCSA-N 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108091060271 Small temporal RNA Proteins 0.000 description 2
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 2
- 102100037054 Voltage-dependent calcium channel subunit alpha-2/delta-3 Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940119059 actemra Drugs 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000012098 association analyses Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001369 bisulfite sequencing Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229950001565 clazakizumab Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229950002507 elsilimomab Drugs 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- PWDYHMBTPGXCSN-UHFFFAOYSA-N n,n'-bis[3,5-bis[n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=NN=C(C)C1=CC(C(=NN=C(N)N)C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(C)=NN=C(N)N)C(C)=NN=C(N)N)=C1 PWDYHMBTPGXCSN-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229950010006 olokizumab Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000003068 pathway analysis Methods 0.000 description 2
- 210000000680 phagosome Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229960001801 proxazole Drugs 0.000 description 2
- OLTAWOVKGWWERU-UHFFFAOYSA-N proxazole Chemical compound C=1C=CC=CC=1C(CC)C1=NOC(CCN(CC)CC)=N1 OLTAWOVKGWWERU-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000003499 redwood Nutrition 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 229950006348 sarilumab Drugs 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229960003323 siltuximab Drugs 0.000 description 2
- 229950006094 sirukumab Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940053017 sylvant Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229960003676 tenidap Drugs 0.000 description 2
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009752 translational inhibition Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- VYPKEODFNOEZGS-VIFPVBQESA-N (2r)-2-acetamido-3-(2-hydroxybenzoyl)sulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSC(=O)C1=CC=CC=C1O VYPKEODFNOEZGS-VIFPVBQESA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- AUDFHJLSHQWFQQ-SFHVURJKSA-N (2s)-2-[[2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetyl]amino]-3-hydroxypropanoic acid Chemical compound CC1=C(CC(=O)N[C@@H](CO)C(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 AUDFHJLSHQWFQQ-SFHVURJKSA-N 0.000 description 1
- XYRIRLDHOQSNLW-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound CC1=C(CC(=O)OC2C3=CC=CC=C3C(=O)O2)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 XYRIRLDHOQSNLW-UHFFFAOYSA-N 0.000 description 1
- SHCYQUDTKWHARF-UHFFFAOYSA-N (3-oxo-1h-2-benzofuran-1-yl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1C2=CC=CC=C2C(=O)O1 SHCYQUDTKWHARF-UHFFFAOYSA-N 0.000 description 1
- ZDHHGGFQZRPUSN-UHFFFAOYSA-N (4-chlorophenyl)-[3-(2h-tetrazol-5-ylmethyl)indol-1-yl]methanone Chemical compound C1=CC(Cl)=CC=C1C(=O)N1C2=CC=CC=C2C(CC2=NNN=N2)=C1 ZDHHGGFQZRPUSN-UHFFFAOYSA-N 0.000 description 1
- PPQZABOURJVKNI-UHFFFAOYSA-N (4-fluorophenyl)-[4-(4-fluorophenyl)-4-hydroxy-1-methylpiperidin-3-yl]methanone Chemical compound C1N(C)CCC(O)(C=2C=CC(F)=CC=2)C1C(=O)C1=CC=C(F)C=C1 PPQZABOURJVKNI-UHFFFAOYSA-N 0.000 description 1
- JFTOCKFCHJCDDX-UVTDQMKNSA-N (4z)-4-benzylidene-5,6,7,8-tetrahydroisoquinoline-1,3-dione Chemical compound C1CCCC2=C1C(=O)NC(=O)\C2=C/C1=CC=CC=C1 JFTOCKFCHJCDDX-UVTDQMKNSA-N 0.000 description 1
- VDNZZIYSCXESNI-ILSZZQPISA-N (6s,8s,9s,10r,11s,13s,14s,17s)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 VDNZZIYSCXESNI-ILSZZQPISA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- ZHXUEUKVDMWSKV-UHFFFAOYSA-N 1-(3,5-ditert-butyl-4-hydroxyphenyl)hex-5-yn-1-one Chemical compound CC(C)(C)C1=CC(C(=O)CCCC#C)=CC(C(C)(C)C)=C1O ZHXUEUKVDMWSKV-UHFFFAOYSA-N 0.000 description 1
- TZGFQIXRVUHDLE-UHFFFAOYSA-N 1-chloro-2-nitro-4-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(C(F)(F)F)=CC=C1Cl TZGFQIXRVUHDLE-UHFFFAOYSA-N 0.000 description 1
- YETULFFXNIHQLK-UHFFFAOYSA-N 1-ethynyl-4-(2-fluorophenyl)benzene Chemical compound FC1=CC=CC=C1C1=CC=C(C#C)C=C1 YETULFFXNIHQLK-UHFFFAOYSA-N 0.000 description 1
- ULIDRMKBVYYVIQ-UHFFFAOYSA-N 1-phenyltetrazol-5-amine Chemical compound NC1=NN=NN1C1=CC=CC=C1 ULIDRMKBVYYVIQ-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- SRETXDDCKMOQNE-UHFFFAOYSA-N 2,3-bis(4-methoxyphenyl)-1h-indole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)C2=CC=CC=C2N1 SRETXDDCKMOQNE-UHFFFAOYSA-N 0.000 description 1
- IZGMROSLQHXRDZ-UHFFFAOYSA-N 2-(1-propyl-4,9-dihydro-3h-pyrano[3,4-b]indol-1-yl)acetic acid Chemical compound N1C2=CC=CC=C2C2=C1C(CCC)(CC(O)=O)OCC2 IZGMROSLQHXRDZ-UHFFFAOYSA-N 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6h-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- ODZUWQAFWMLWCF-UHFFFAOYSA-N 2-(3-phenyl-1-benzofuran-7-yl)propanoic acid Chemical compound C=1OC=2C(C(C(O)=O)C)=CC=CC=2C=1C1=CC=CC=C1 ODZUWQAFWMLWCF-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- IDCAZKFFVIMCCS-UHFFFAOYSA-N 2-[3-(4-chlorophenyl)-4-imino-2-oxoimidazolidin-1-yl]acetonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)N(CC#N)CC1=N IDCAZKFFVIMCCS-UHFFFAOYSA-N 0.000 description 1
- ANMLJLFWUCQGKZ-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]-3-pyridinecarboxylic acid (3-oxo-1H-isobenzofuran-1-yl) ester Chemical compound FC(F)(F)C1=CC=CC(NC=2C(=CC=CN=2)C(=O)OC2C3=CC=CC=C3C(=O)O2)=C1 ANMLJLFWUCQGKZ-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- NLGUJWNOGYWZBI-UHFFFAOYSA-N 2-[3-chloro-4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 NLGUJWNOGYWZBI-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- QKKLKGVIECOSRM-CODXZCKSSA-N 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol;4-[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21.O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 QKKLKGVIECOSRM-CODXZCKSSA-N 0.000 description 1
- LNXXSBRGLBOASF-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-4-methyl-1,3-oxazol-5-yl]methoxy]-2-methylpropanoic acid Chemical compound O1C(COC(C)(C)C(O)=O)=C(C)N=C1C1=CC=C(Cl)C=C1 LNXXSBRGLBOASF-UHFFFAOYSA-N 0.000 description 1
- GXEUNRBWEAIPCN-UHFFFAOYSA-N 2-chloro-2-(3-chloro-4-cyclohexylphenyl)acetic acid Chemical compound ClC1=CC(C(Cl)C(=O)O)=CC=C1C1CCCCC1 GXEUNRBWEAIPCN-UHFFFAOYSA-N 0.000 description 1
- 101150042997 21 gene Proteins 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- PYSICVOJSJMFKP-UHFFFAOYSA-N 3,5-dibromo-2-chloropyridine Chemical compound ClC1=NC=C(Br)C=C1Br PYSICVOJSJMFKP-UHFFFAOYSA-N 0.000 description 1
- PLZMRGRLCWCLFW-UHFFFAOYSA-N 3-[5-(3-bromophenyl)tetrazol-2-yl]-1-piperidin-1-ylpropan-1-one Chemical compound BrC1=CC=CC(C2=NN(CCC(=O)N3CCCCC3)N=N2)=C1 PLZMRGRLCWCLFW-UHFFFAOYSA-N 0.000 description 1
- YLJRTDTWWRXOFG-UHFFFAOYSA-N 3-[5-(4-chlorophenyl)furan-2-yl]-3-hydroxypropanoic acid Chemical compound O1C(C(CC(O)=O)O)=CC=C1C1=CC=C(Cl)C=C1 YLJRTDTWWRXOFG-UHFFFAOYSA-N 0.000 description 1
- YUORBURTMIUPMW-UHFFFAOYSA-N 3-methyl-5-[2-(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)ethyl]-1,3-oxazolidin-2-one Chemical compound O1C(=O)N(C)CC1CCN1CC=C(C=2C=CC=CC=2)CC1 YUORBURTMIUPMW-UHFFFAOYSA-N 0.000 description 1
- PIAMNHTVFPWVHG-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.N1C=NC(C=2C=CC(Cl)=CC=2)=C1C PIAMNHTVFPWVHG-UHFFFAOYSA-N 0.000 description 1
- INDZCVYWKNWKIQ-UHFFFAOYSA-N 4-(fluoren-9-ylidenemethyl)benzenecarboximidamide;hydrochloride Chemical compound Cl.C1=CC(C(=N)N)=CC=C1C=C1C2=CC=CC=C2C2=CC=CC=C21 INDZCVYWKNWKIQ-UHFFFAOYSA-N 0.000 description 1
- LQVMQEYROPXMQH-UHFFFAOYSA-N 4-dibenzofuran-2-yl-4-oxobutanoic acid Chemical compound C1=CC=C2C3=CC(C(=O)CCC(=O)O)=CC=C3OC2=C1 LQVMQEYROPXMQH-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- CXSJGNHRBWJXEA-UHFFFAOYSA-N 5,12-dihydrophthalazino[3,2-b]phthalazine-7,14-dione Chemical compound C1C2=CC=CC=C2C(=O)N2N1C(=O)C1=CC=CC=C1C2 CXSJGNHRBWJXEA-UHFFFAOYSA-N 0.000 description 1
- HEOZYYOUKGGSBJ-UHFFFAOYSA-N 5-(4-methoxybenzoyl)-2,3-dihydro-1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C2N1CCC2C(O)=O HEOZYYOUKGGSBJ-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- OAIZNWQBWDHNIH-UHFFFAOYSA-N 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)quinazolin-2-one Chemical compound N=1C(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 OAIZNWQBWDHNIH-UHFFFAOYSA-N 0.000 description 1
- XWXVKXXKKLBDDJ-UHFFFAOYSA-N 7-chloro-3,3a-dihydro-2h-[1,2]oxazolo[3,2-b][1,3]benzoxazin-9-one Chemical compound O1C2CCON2C(=O)C2=CC(Cl)=CC=C21 XWXVKXXKKLBDDJ-UHFFFAOYSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- ZOCUOMKMBMEYQV-GSLJADNHSA-N 9alpha-Fluoro-11beta,17alpha,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ZOCUOMKMBMEYQV-GSLJADNHSA-N 0.000 description 1
- 101150092476 ABCA1 gene Proteins 0.000 description 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102100034542 Acyl-CoA (8-3)-desaturase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 101150018129 CSF2 gene Proteins 0.000 description 1
- 101150069031 CSN2 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KATBVKFXGKGUFE-UHFFFAOYSA-N Cintazone Chemical compound C12=CC=CC=C2N2C(=O)C(CCCCC)C(=O)N2C=C1C1=CC=CC=C1 KATBVKFXGKGUFE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- YXKFATPOEMHNMJ-KJEYTGHBSA-N Cormethasone acetate Chemical compound C1C(F)(F)C2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O YXKFATPOEMHNMJ-KJEYTGHBSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 108050002829 DNA (cytosine-5)-methyltransferase 3A Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- 102100031788 E3 ubiquitin-protein ligase MYLIP Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108091029499 Group II intron Proteins 0.000 description 1
- 102100040505 HLA class II histocompatibility antigen, DR alpha chain Human genes 0.000 description 1
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 101000848239 Homo sapiens Acyl-CoA (8-3)-desaturase Proteins 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101001128447 Homo sapiens E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 1
- 101000839025 Homo sapiens Hydroxymethylglutaryl-CoA synthase, cytoplasmic Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000896726 Homo sapiens Lanosterol 14-alpha demethylase Proteins 0.000 description 1
- 101000740227 Homo sapiens Lathosterol oxidase Proteins 0.000 description 1
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- 101000713288 Homo sapiens Solute carrier family 22 member 5 Proteins 0.000 description 1
- 101001056878 Homo sapiens Squalene monooxygenase Proteins 0.000 description 1
- 101000878981 Homo sapiens Squalene synthase Proteins 0.000 description 1
- 101000631826 Homo sapiens Stearoyl-CoA desaturase Proteins 0.000 description 1
- 101000612875 Homo sapiens Testis-specific Y-encoded-like protein 1 Proteins 0.000 description 1
- 102100028888 Hydroxymethylglutaryl-CoA synthase, cytoplasmic Human genes 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 101150097648 Il1a gene Proteins 0.000 description 1
- 206010056997 Impaired fasting glucose Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100021695 Lanosterol 14-alpha demethylase Human genes 0.000 description 1
- 102100037199 Lathosterol oxidase Human genes 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- HUXCOHMTWUSXGY-GAPIFECDSA-N Meclorisone dibutyrate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2Cl HUXCOHMTWUSXGY-GAPIFECDSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- XWALNWXLMVGSFR-HLXURNFRSA-N Methandrostenolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 XWALNWXLMVGSFR-HLXURNFRSA-N 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 101100385413 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) csm-3 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229940127355 PCSK9 Inhibitors Drugs 0.000 description 1
- 101710121660 PDZ and LIM domain protein 7 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100026651 Pro-adrenomedullin Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010027647 Replication Protein C Proteins 0.000 description 1
- 102100037851 Replication factor C subunit 2 Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 102100025560 Squalene monooxygenase Human genes 0.000 description 1
- 102100037997 Squalene synthase Human genes 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102100040953 Testis-specific Y-encoded-like protein 1 Human genes 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108091026822 U6 spliceosomal RNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MVLBCBPGBUAVJQ-CENSZEJFSA-N [(6s,8s,9r,10s,11s,13s,14s,16r,17r)-17-(chloromethylsulfanylcarbonyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O MVLBCBPGBUAVJQ-CENSZEJFSA-N 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010045606 actin kinase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960005142 alclofenac Drugs 0.000 description 1
- ARHWPKZXBHOEEE-UHFFFAOYSA-N alclofenac Chemical compound OC(=O)CC1=CC=C(OCC=C)C(Cl)=C1 ARHWPKZXBHOEEE-UHFFFAOYSA-N 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- LSWBQIAZNGURQV-WTBIUSKOSA-N algestone acetonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)C)[C@@]1(C)CC2 LSWBQIAZNGURQV-WTBIUSKOSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- NSZFBGIRFCHKOE-LFZVSNMSSA-N amcinafal Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(CC)(CC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O NSZFBGIRFCHKOE-LFZVSNMSSA-N 0.000 description 1
- 229950004850 amcinafal Drugs 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229950004699 anirolac Drugs 0.000 description 1
- 229950002412 anitrazafen Drugs 0.000 description 1
- HDNJXZZJFPCFHG-UHFFFAOYSA-N anitrazafen Chemical compound C1=CC(OC)=CC=C1C1=NN=C(C)N=C1C1=CC=C(OC)C=C1 HDNJXZZJFPCFHG-UHFFFAOYSA-N 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960000560 balsalazide disodium Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960005149 bendazac Drugs 0.000 description 1
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- UIDLJTHRRPMIQP-UHFFFAOYSA-L bis[2-[4-(2-methylpropyl)phenyl]propanoyloxy]aluminum;hydrate Chemical compound O.C1=CC(CC(C)C)=CC=C1C(C)C(=O)O[Al]OC(=O)C(C)C1=CC=C(CC(C)C)C=C1 UIDLJTHRRPMIQP-UHFFFAOYSA-L 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960001780 bromelains Drugs 0.000 description 1
- 229950011622 broperamole Drugs 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- CKMOQBVBEGCJGW-UHFFFAOYSA-L chembl1200760 Chemical compound [Na+].[Na+].C1=C(C([O-])=O)C(O)=CC=C1N=NC1=CC=C(C(=O)NCCC([O-])=O)C=C1 CKMOQBVBEGCJGW-UHFFFAOYSA-L 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229950002545 cicloprofen Drugs 0.000 description 1
- GPUVGQIASQNZET-CCEZHUSRSA-N cinnoxicam Chemical compound C=1C=CC=CC=1/C=C/C(=O)OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 GPUVGQIASQNZET-CCEZHUSRSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229950005384 cliprofen Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- SJCRQMUYEQHNTC-UHFFFAOYSA-N clopirac Chemical compound CC1=CC(CC(O)=O)=C(C)N1C1=CC=C(Cl)C=C1 SJCRQMUYEQHNTC-UHFFFAOYSA-N 0.000 description 1
- 229950009185 clopirac Drugs 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150055601 cops2 gene Proteins 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- ZHPBLHYKDKSZCQ-UHFFFAOYSA-N cyclooctylmethanol Chemical compound OCC1CCCCCCC1 ZHPBLHYKDKSZCQ-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 229940075844 delatestryl Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 229940094111 depo-testosterone Drugs 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229960004515 diclofenac potassium Drugs 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- 229950007956 diftalone Drugs 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- GZBONOYGBJSTHF-QLRNAMTQSA-N drocinonide Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O GZBONOYGBJSTHF-QLRNAMTQSA-N 0.000 description 1
- 229950006082 drocinonide Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229950003801 epirizole Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ULANGSAJTINEBA-UHFFFAOYSA-N ethyl n-(3-benzoylphenyl)-n-(trifluoromethylsulfonyl)carbamate Chemical compound CCOC(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ULANGSAJTINEBA-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229950003579 fenamole Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229950006236 fenclofenac Drugs 0.000 description 1
- IDKAXRLETRCXKS-UHFFFAOYSA-N fenclofenac Chemical compound OC(=O)CC1=CC=CC=C1OC1=CC=C(Cl)C=C1Cl IDKAXRLETRCXKS-UHFFFAOYSA-N 0.000 description 1
- 229950003537 fenclorac Drugs 0.000 description 1
- 229950005416 fendosal Drugs 0.000 description 1
- HAWWPSYXSLJRBO-UHFFFAOYSA-N fendosal Chemical compound C1=C(O)C(C(=O)O)=CC(N2C(=CC=3C4=CC=CC=C4CCC=32)C=2C=CC=CC=2)=C1 HAWWPSYXSLJRBO-UHFFFAOYSA-N 0.000 description 1
- 229950002296 fenpipalone Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229950004322 flazalone Drugs 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229950005288 flumizole Drugs 0.000 description 1
- OPYFPDBMMYUPME-UHFFFAOYSA-N flumizole Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OC)=CC=2)NC(C(F)(F)F)=N1 OPYFPDBMMYUPME-UHFFFAOYSA-N 0.000 description 1
- WEGNFRKBIKYVLC-XTLNBZDDSA-N flunisolide acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WEGNFRKBIKYVLC-XTLNBZDDSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000469 flunixin meglumine Drugs 0.000 description 1
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 description 1
- 229950008509 fluocortin butyl Drugs 0.000 description 1
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 description 1
- 229960001629 fluorometholone acetate Drugs 0.000 description 1
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 1
- 229950007253 fluquazone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229950003750 fluretofen Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 229950008156 furaprofen Drugs 0.000 description 1
- 229950006099 furobufen Drugs 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229950004611 halopredone acetate Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229950009183 ibufenac Drugs 0.000 description 1
- CYWFCPPBTWOZSF-UHFFFAOYSA-N ibufenac Chemical compound CC(C)CC1=CC=C(CC(O)=O)C=C1 CYWFCPPBTWOZSF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960004260 indomethacin sodium Drugs 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 229950008443 indoxole Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229950004204 intrazole Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960003317 isoflupredone acetate Drugs 0.000 description 1
- QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
- 229950011455 isoxepac Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- GQVWFGYYMWLERN-UHFFFAOYSA-J magnesium;2-carboxyphenolate;2-hydroxyethyl(trimethyl)azanium;sulfate;tetrahydrate Chemical compound O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O GQVWFGYYMWLERN-UHFFFAOYSA-J 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OJGJQQNLRVNIKE-UHFFFAOYSA-N meseclazone Chemical compound O1C2=CC=C(Cl)C=C2C(=O)N2C1CC(C)O2 OJGJQQNLRVNIKE-UHFFFAOYSA-N 0.000 description 1
- 229950000701 meseclazone Drugs 0.000 description 1
- UXYRZJKIQKRJCF-TZPFWLJSSA-N mesterolone Chemical compound C1C[C@@H]2[C@@]3(C)[C@@H](C)CC(=O)C[C@@H]3CC[C@H]2[C@@H]2CC[C@H](O)[C@]21C UXYRZJKIQKRJCF-TZPFWLJSSA-N 0.000 description 1
- 229960005272 mesterolone Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960003377 metandienone Drugs 0.000 description 1
- 229960003578 metenolone Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960005270 methenolone acetate Drugs 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229950010796 methylprednisolone suleptanate Drugs 0.000 description 1
- CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- NKDJNEGDJVXHKM-UHFFFAOYSA-N n,2-dimethyl-4,5,6,7-tetrahydroindazol-3-amine Chemical compound C1CCCC2=NN(C)C(NC)=C21 NKDJNEGDJVXHKM-UHFFFAOYSA-N 0.000 description 1
- HWCORKBTTGTRDY-UHFFFAOYSA-N n-(4-chlorophenyl)-1,3-dioxo-4h-isoquinoline-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1NC(=O)C1C2=CC=CC=C2C(=O)NC1=O HWCORKBTTGTRDY-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229950006890 naproxol Drugs 0.000 description 1
- LTRANDSQVZFZDG-SNVBAGLBSA-N naproxol Chemical compound C1=C([C@H](C)CO)C=CC2=CC(OC)=CC=C21 LTRANDSQVZFZDG-SNVBAGLBSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229950006046 nimazone Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960004364 olsalazine sodium Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960004534 orgotein Drugs 0.000 description 1
- 108010070915 orgotein Proteins 0.000 description 1
- 229950003655 orpanoxin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 229960005244 oxymetholone Drugs 0.000 description 1
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 1
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- 229960001369 piroxicam cinnamate Drugs 0.000 description 1
- 229960000851 pirprofen Drugs 0.000 description 1
- PIDSZXPFGCURGN-UHFFFAOYSA-N pirprofen Chemical compound ClC1=CC(C(C(O)=O)C)=CC=C1N1CC=CC1 PIDSZXPFGCURGN-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229960003611 pramlintide Drugs 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229950008421 prednazate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- WAAVMZLJRXYRMA-UHFFFAOYSA-N prifelone Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C(=O)C=2SC=CC=2)=C1 WAAVMZLJRXYRMA-UHFFFAOYSA-N 0.000 description 1
- 229950004465 prifelone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229950003795 prodolic acid Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960002466 proquazone Drugs 0.000 description 1
- JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001886 rilonacept Drugs 0.000 description 1
- 108010046141 rilonacept Proteins 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229950001166 romazarit Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229950000125 salcolex Drugs 0.000 description 1
- 229950009768 salnacedin Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229950011197 sanguinarium chloride Drugs 0.000 description 1
- GIZKAXHWLRYMLE-UHFFFAOYSA-M sanguinarium chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 GIZKAXHWLRYMLE-UHFFFAOYSA-M 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229950002093 seclazone Drugs 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229950006250 sermetacin Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HVBBVDWXAWJQSV-UHFFFAOYSA-N sodium;(3-benzoylphenyl)-(difluoromethylsulfonyl)azanide Chemical compound [Na+].FC(F)S(=O)(=O)[N-]C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 HVBBVDWXAWJQSV-UHFFFAOYSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- JMHRGKDWGWORNU-UHFFFAOYSA-M sodium;2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate Chemical compound [Na+].CC1=C(CC([O-])=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 JMHRGKDWGWORNU-UHFFFAOYSA-M 0.000 description 1
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- TVGNJNYKOTWAJQ-UHFFFAOYSA-M sodium;4-butyl-5-oxo-1,2-diphenylpyrazol-3-olate;propane-1,2,3-triol Chemical compound [Na+].OCC(O)CO.C=1C=CC=CC=1N1C(=O)C(CCCC)=C([O-])N1C1=CC=CC=C1 TVGNJNYKOTWAJQ-UHFFFAOYSA-M 0.000 description 1
- AVERBMQHYOZACV-UHFFFAOYSA-M sodium;7-chloro-4-[(3,4-dichlorophenyl)carbamoyl]-1,1-dioxo-2,3-dihydro-1$l^{6}-benzothiepin-5-olate;hydrate Chemical compound O.[Na+].C1CS(=O)(=O)C2=CC=C(Cl)C=C2C([O-])=C1C(=O)NC1=CC=C(Cl)C(Cl)=C1 AVERBMQHYOZACV-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229950005100 talmetacin Drugs 0.000 description 1
- 229960005262 talniflumate Drugs 0.000 description 1
- 229950005400 talosalate Drugs 0.000 description 1
- 229950003441 tebufelone Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229950007324 tesicam Drugs 0.000 description 1
- 229950000997 tesimide Drugs 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229950002345 tiopinac Drugs 0.000 description 1
- 229960003114 tixocortol pivalate Drugs 0.000 description 1
- BISFDZNIUZIKJD-XDANTLIUSA-N tixocortol pivalate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CSC(=O)C(C)(C)C)(O)[C@@]1(C)C[C@@H]2O BISFDZNIUZIKJD-XDANTLIUSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960002044 tolmetin sodium Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950008073 triclonide Drugs 0.000 description 1
- VSVSLEMVVAYTQW-VSXGLTOVSA-N triclonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]2(C)C[C@@H]1Cl VSVSLEMVVAYTQW-VSXGLTOVSA-N 0.000 description 1
- 229950000451 triflumidate Drugs 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229950007802 zidometacin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- CVD cardiovascular disease
- compositions and methods for diagnosing and treating inflammatory diseases based on the disclosed overexpression and hypomethylation of ARID5B that is associated with an increased risk of inflammatory disease.
- a method that involves obtaining a sample from a subject, such as a subject having or suspected of having an inflammatory disease, and assaying the sample for ARID5B gene expression, or for methylation of an ARID5B CpG site that is negatively correlated with ARID5B gene expression.
- the CpG methylation site is one or more of the underlined CpG site found in the nucleic acid sequence: ATAAATATTYGGTGTTATAATAGAGTAGTAATTAAATGGAAATTTTAATATA ATTGTTAATAGTAGTAAGAATTGGAATAGYGTTAGGTATATAAAGTTGATGTTTTG TYGTTGGTTGGTTGTTAGGAGTATAGTGA (SEQ ID NO:1).
- the CpG methylation site can be cg25953130.
- Also disclosed is a method for diagnosing or prognosing an inflammatory disease in a subject that involves assaying a sample from the subject for ARID5B expression levels, wherein detection of elevated ARID5B expression levels compared to a control is an indication that the subject has an inflammatory disease. Since methylation of the disclosed ARID5B CpG sites negatively correlate with ARID5B gene expression, in some embodiments, ARID5B expression levels are assayed by assaying for methylation of the ARID5B CpG sites.
- the inflammatory disease of the disclosed methods can be selected from the group comprising diabetes mellitus type 2 or a cardiovascular diseases (e.g.
- Also disclosed is a method for treating an inflammatory disease in a subject that involves obtaining a sample from a subject having or suspected of having an inflammatory disease, assaying the sample for ARID5B expression levels, and treating the subject for an inflammatory disease if the ARID5B expression levels are elevated compared to a control.
- the subject presents with a high risk for cardiovascular diseases (CVD), e.g. based on family history, obesity, diabetes, hyperlipidemia, hypertension, or prior incidence of CVD.
- CVD cardiovascular diseases
- the subject can be treated for CVD if ARID5B expression levels are elevated.
- Treatment for cardiovascular disease include lifestyle changes (e.g. diet and exercise), statins, and/or blood thinners.
- the subject is treated with an antiinflammatory agent ⁇ f ARID5B expression levels are elevated.
- the choice of treatment is based on the level of ARID5B expression.
- the disclosed methods use ARID5B expression levels to stratify subjects based on disease risk. Subjects determined to be at higher risk based on elevated ARID5B expression can be treated with standard of care for that risk, including the use of aggressive treatments earlier than would otherwise be used. For example, all subjects with CVD should be recommended lifestyle modification.
- ARID5B levels elevate the subject can be treated with a statin.
- the subject can be further treated with ezetimibe and/or PCSK9 inhibitors.
- levels elevate even further, the subject can be further treated with a PCSK9 antibody.
- the subject presents with a high risk for diabetes or pre-diabetes, e.g.
- the subject is treated for diabetes or pre-diabetes if ARID5B expression levels are elevated.
- Treatment for diabetes include lifestyle changes (diet and exercise), metformin, insulin, sulfonylurea, GLP-1 agonists, thiazolidinedione, glinide, SGLT2 inhibitors, DDP-4 inhibitorss, alpha- glucosidase inhibitors, and pramlintide.
- the subject is treated with an anti-inflammatory agent ⁇ ARID5B expression levels are elevated. In some cases, the choice of treatment is based on the level of ARID5B expression.
- ARID5B expression levels are used to screen subjects for the presence or risk of an inflammatory disease, such as CVD or diabetes, before the subject presents with any clinical symptoms.
- detection of elevated ARID5B expression levels can be an indication that the subject should be screened for an inflammatory disease, such as CVD or diabetes.
- the subject is directed to make lifestyle changes (e.g. diet and exercise) to reduce the risk of disease onset.
- the subject is treated prophylactically with antiinflammatory agents to prevent the onset of an inflammatory disease.
- the subject is treated using standards of care for CVD and/or diabetes prevention, e.g. statins.
- a method of treating a subject with elevated ARID5B expression levels that involves administering to the subject an anti-inflammatory agent.
- the subject having elevated ARID5B expression levels is treated with an anti-IL6 drug, such as tocilizumab (Actemra), siltuximab (Sylvant), Sarilumab, clazakizumab, olokizumab (CDP6038), elsilimomab, BMS-945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ARGX-109, FE301, and FM101.
- an anti-IL6 drug such as tocilizumab (Actemra), siltuximab (Sylvant), Sarilumab, clazakizumab, olokizumab (CDP6038), elsilimomab, BMS-945429(ALD518), sirukumab (CNTO
- Also disclosed is a method for treating a subject with an inflammatory disease that involves administering to the subject a composition comprising an ARID5B inhibitor in an amount effective to reduce endogenous expression levels of ARID5B in the subject.
- the ARID5B inhibitor is a gene silencing agent.
- the gene silencing agent can be an antisense oligonucleotide, siRNA, or shRNA.
- the ARID5B inhibitor is a CRISPR-Cas system that methylates a disclosed ARID5B CpG site that negatively correlates with ARID5B gene expression.
- the method prior to treatment, the method further comprises detecting elevated ARID5B expression levels in a sample from the subject. Since methylation of the disclosed ARID5B CpG sites negatively correlate with ARID5B gene expression, in some embodiments, ARID5B expression levels are assayed by assaying for methylation of the ARID5B CpG sites.
- FIG. 1 Transcriptomic associations with Carotid Plaque and CAC Scores in 1 ,208 MESA participants.
- the two volcano plots showing effect size ( ⁇ ) of -logl 0(p- value) for associations of each mRNA expression (for 10,989 unique mRNA expression) with A) carotid plaque score and B) CAC.
- the red line illustrates the threshold for an FDR ⁇ 0.05 (linear regression adjusting for age, sex, race, and study site).
- Expression of ARID5B and PDLIM7 were associated with both carotid plaque and CAC score; green star indicates mRNA expression most significantly associated with carotid plaque or CAC.
- Figure 2 Methylomic associations with Carotid Plaque and CAC Scores in 1,208 MESA participants.
- the two Manhattan plots showing chromosomal locations of -loglO(p-value) for associations of each CpG site (for 484,817 CpG sites) with A) carotid plaque score and B) CAC score.
- the red line illustrates the threshold for an FDR ⁇ 0.05; linear regression adjusting for age, sex, race, and study site).
- One CpG at ILVBL (bolded, green dot) was associated with both carotid plaque and CAC; green star indicates CpGs most significantly associated with carotid plaque or CAC.
- ARID5B mRNA expression is significantly negatively correlated (Pearson r) with methylation of a CpG (cg25953130) in 1,264 CD14+ samples from MESA participants.
- chr position on chromosome (chr) 10) is shown in the top panel; the bottom panel shows the ARID5B expression-associated CpG (cg25953130, chrl 0:63,753,550, hg19, indicated by the light blue line) located in an ARID5B intron, overlaps a DNase hypersensitive site in a CD14+ sample from BLUEPRINT, histone marks indicative of a strong enhancer/promoter in a CD14+ and B cell line sample from BLUEPRINT and ENCODE (see Supplementary Fig. 3 for ChromHMM color code), as well as a transcription factor binding site for EP300, detected in a neuroblastoma cell line (SK- N-SH_RA).
- CpG cg25953130, chrl 0:63,753,550, hg19, indicated by the light blue line
- a physical interaction is detected between the ARID5B promoter and the region near the ARID5B CpG cg25953130 by both HiC and ChlA-PET data.
- the heatmap (white, low; red, high; top panel) graphically displays Hi-C interaction counts (the normalized number of contacts between a pair of loci) for the large region surrounding ARID5B in a B cell line (GM12878; reported by Rao et al. 2014); active enhancer marks (H3K27ac and H3K4me1 in GM12878 from ENCODE) are shown below; the bottom panel zooms in on ARID5B (blue highlighted region) Hi-C interaction.
- ARID5B expression and methylation are associated with subclinical and clinical CVD risk. Odds ratio of subclinical and clinical CVD (in the full model with adjustment of traditional CVD risk factors and statin use) by tertiles of A) ARID5B mRNA expression and B) ARID5B methylation (cg25953130).
- Figures 6A and 6B Histograms of subclinical CVD phenotypes.
- FIGS. 7A to 7D Reproducibility of Microarray mRNA Expression and DNA
- Methylomic Data Overtime A) Correlation of the repeated measurements of transcriptomic profiles for one subject between two visits 5-month apart; B) correlation of transcriptomic profiles between two subjects at visit 1 ; C) Correlation of the repeated measurements of methylomic profiles for one subject between two visits 5-month apart; D) correlation of methylomic profiles between two subjects at visit 1.
- FIG. 8 Chromatin Map of Monocytes.
- Six chromatin states (top panel) predicted using ChromHMM and four CD14+ histone marks (from BLUEPRINT) are enriched with various genomic features (middle panel); annotation of the six chromatin states is provided (bottom panel).
- selected key inflammatory response genes including cytokine, interferon signaling, and antigen processing and presentation genes
- FIGS. 10A and 10B Time Course of LPS-induced TNF and IL1A Gene
- THP1 monocytes Gene expression of (A) TNF and (B) IL1A, in LPS (100 ng/ml) stimulated THP1 cells.
- Figures 11A and 11B are bar graphs showing diabetes (Fig. 11A) and subclinical CVD (Fig. 11B) risk as a function of ARID5B expression with
- Ranges can be expressed herein as from “about” one particular value, and/or to "about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about” that particular value in addition to the value itself. For example, if the value "10” is disclosed, then “about 10" is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11 , 12, 13, and 14 are also disclosed.
- the term "subject” refers to the target of administration, e.g., an animal.
- the subject of the herein disclosed methods can be a vertebrate, such as a mammal.
- the subject of the herein disclosed methods can be a human.
- the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
- the subject is a patient.
- a patient refers to a subject afflicted with a disease or disorder, such as, for example, cancer and/or aberrant cell growth.
- patient includes human and veterinary subjects.
- the subject has been diagnosed with a need for treatment for an inflammatory disease.
- the subject has not yet been diagnosed and the disclosed methods to predict a higher risk for developing an inflammatory disease.
- treating refers to curative therapy, prophylactic therapy, or preventative therapy.
- the terms refers to the medical management of a subject or a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder, such as, for example, cancer or a tumor.
- This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder.
- this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.
- the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
- a mammal e.g., a human
- administering refers to any method of providing a composition to a subject.
- Such methods include, but are not limited to, intracardiac administration, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration.
- Administration can be continuous or intermittent.
- a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition.
- a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
- contacting refers to bringing a disclosed composition or peptide or pharmaceutical preparation and a cell, target receptor, or other biological entity together in such a manner that the compound can affect the activity of the target (e.g., receptor, transcription factor, cell, etc.), either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent.
- the target e.g., receptor, transcription factor, cell, etc.
- an effective amount of the polymeric nanoparticle is an amount that kills and/or inhibits the growth of cells without causing extraneous damage to surrounding non-cancerous cells.
- amount effective refers to an amount that kills and/or inhibits the growth of cells without causing extraneous damage to surrounding non-cancerous cells.
- therapeutically effective amount refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
- pharmaceutically acceptable describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner.
- pharmaceutically acceptable carrier refers to sterile aqueous or
- nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol and the like
- carboxymethylcellulose and suitable mixtures thereof include vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption.
- adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents.
- Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the inject
- Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use.
- Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
- RNA silencing agent refers to an RNA which is capable of preventing complete processing (e.g, the full translation and/or
- RNA silencing agents include small ( ⁇ 50 b.p.), noncoding RNA molecules, for example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated.
- exemplary RNA silencing agents include siRNAs, miRNAs, and siRNA-like duplexes, as well as precursors thereof.
- small interfering RNA refers to an RNA (or RNA analog) comprising between about 10-50 nucleotides (or nucleotide analogs) which is capable of directing or mediating RNA interference.
- an siRNA comprises between about 15-30 nucleotides or nucleotide analogs, more preferably between about 16-25 nucleotides (or nucleotide analogs), even more preferably between about 18-23 nucleotides (or nucleotide analogs), and even more preferably between about 19-22 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides or nucleotide analogs).
- miRNA miRNA
- small temporal RNAs small temporal RNAs
- stRNAs small temporal RNAs
- a "natural miRNA” refers to a microRNA that occurs naturally.
- miRNA disorder shall refer to a disease or disorder characterized by a aberrant expression or activity of a natural miRNA.
- RNA interference refers to a selective intracellular degradation of RNA.
- RNAi occurs in cells naturally to remove foreign RNAs (e.g., viral RNAs). Natural RNAi proceeds via fragments cleaved from free dsRNA which direct the degradative mechanism to other similar RNA sequences.
- translational repression refers to a selective inhibition of mRNA translation. Natural translational repression proceeds via miRNAs cleaved from shRNA precursors. Both RNAi and translational repression are mediated by RISC. Both RNAi and translational repression occur naturally or can be initiated by the hand of man, for example, to silence the expression of target genes.
- the term "antisense strand" of an siRNA or RNAi agent refers to a strand that is substantially complementary to a section of about 10-50 nucleotides, e.g., about 15-30, 16-25, 18-23 or 19-22 nucleotides of the mRNA of the gene targeted for silencing.
- the antisense strand or first strand has sequence sufficiently complementary to the desired target mRNA sequence to direct target- specific RNA interference (RNAi), e.g., complementarity sufficient to trigger the destruction of the desired target mRNA by the RNAi machinery or process (RNAi interference) or complementarity sufficient to trigger translational repression of the desired target mRNA.
- RNAi target-specific RNA interference
- siRNA duplex intermediates or siRNA-like duplexes include a miRNA strand having sufficient complementarity to a section of about 10-50 nucleotides of the mRNA of the gene targeted for silencing and a miRNA* strand having sufficient complementarity to form a duplex with the miRNA strand.
- guide strand refers to a strand of an RNAi agent, e.g., an antisense strand of an siRNA duplex, that enters into the RISC complex and directs cleavage of the target mRNA.
- RNA interference RNA interference
- inflammatory disease and "inflammatory disorder” refer to diseases, disorders, and conditions characterized by abnormal inflammation. Examples include type 2 diabetes and cardiovascular diseases, such as
- the term "anti-inflammatory agent” refers to substance or treatment that reduce inflammation or swelling.
- the anti-inflammatory agent can be an anti-IL6 drug, such as tocilizumab (Actemra), siltuximab (Sylvant), Sarilumab, clazakizumab, olokizumab (CDP6038), elsilimomab, BMS- 945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ARGX-109, FE301, and FM101.
- the anti-inflammatory agent can be an anti-IL1 drug, such as canakinumab or rilonacept.
- Alclometasone Dipropionate Algestone Acetonide, alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen,
- Benzydamine Hydrochloride Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate,
- Clopirac Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Decanoate, Deflazacort, Delatestryl, Depo-Testosterone, Desonide, Desoximetasone,
- Methods of "determining gene expression levels” include methods that quantify levels of gene transcripts as well as methods that determine whether a gene of interest is expressed at all.
- a measured expression level may be expressed as any quantitative value, for example, a fold-change in expression, up or down, relative to a control gene or relative to the same gene in another sample, or a log ratio of expression, or any visual representation thereof, such as, for example, a "heatmap" where a color intensity is representative of the amount of gene expression detected.
- Exemplary methods for detecting the level of expression of a gene include, but are not limited to, Northern blotting, dot or slot blots, reporter gene matrix, nuclease protection, RT-PCR, microarray profiling, differential display, 2D gel electrophoresis, SELDI-TOF, ICAT, enzyme assay, antibody assay, and MNAzyme-based detection methods.
- a gene whose level of expression is to be detected may be amplified, for example by methods that may include one or more of: polymerase chain reaction (PCR), strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), transcription- mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), or reverse transcription polymerase chain reaction (RT-PCR).
- PCR polymerase chain reaction
- SDA strand displacement amplification
- LAMP loop-mediated isothermal amplification
- RCA rolling circle amplification
- TMA transcription- mediated amplification
- TMA transcription- mediated amplification
- NASBA self-sustained sequence replication
- RT-PCR reverse transcription polymerase chain reaction
- Numerous technological platforms for performing high throughput expression analysis are known. Generally, such methods involve a logical or physical array of either the subject samples, the biomarkers, or both.
- Common array formats include both liquid and solid phase arrays.
- assays employing liquid phase arrays e.g., for hybridization of nucleic acids, binding of antibodies or other receptors to ligand, etc.
- Microtiter plates with 96, 384 or 1536 wells are widely available, and even higher numbers of wells, e.g., 3456 and 9600 can be used.
- microtiter plates are determined by the methods and equipment, e.g., robotic handling and loading systems, used for sample preparation and analysis.
- exemplary systems include, e.g., xMAP® technology from Luminex (Austin, TX), the SECTOR® Imager with MULTI-ARRAY® and MULTI-SPOT® technologies from Meso Scale Discovery (Gaithersburg, MD), the ORCATM system from Beckman-Coulter, Inc. (Fullerton, Calif.) and the ZYMATETM systems from Zymark Corporation (Hopkinton, MA), miRCURY LNATM microRNA Arrays (Exiqon, Woburn, MA).
- solid phase arrays can favorably be employed to determine expression patterns in the context of the disclosed methods, assays and kits.
- Exemplary formats include membrane or filter arrays (e.g., nitrocellulose, nylon), pin arrays, and bead arrays (e.g., in a liquid "slurry").
- probes corresponding to nucleic acid or protein reagents that specifically interact with (e.g., hybridize to or bind to) an expression product corresponding to a member of the candidate library are immobilized, for example by direct or indirect cross-linking, to the solid support.
- any solid support capable of withstanding the reagents and conditions necessary for performing the particular expression assay can be utilized.
- functionalized glass silicon, silicon dioxide, modified silicon, any of a variety of polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof can all serve as the substrate for a solid phase array.
- polymers such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof can all serve as the substrate for a solid phase array.
- the array is a "chip" composed, e.g., of one of the above- specified materials.
- Polynucleotide probes e.g., RNA or DNA, such as cDNA, synthetic oligonucleotides, and the like, or binding proteins such as antibodies or antigen-binding fragments or derivatives thereof, that specifically interact with expression products of individual components of the candidate library are affixed to the chip in a logically ordered manner, i.e., in an array.
- any molecule with a specific affinity for either the sense or anti-sense sequence of the marker nucleotide sequence can be fixed to the array surface without loss of specific affinity for the marker and can be obtained and produced for array production, for example, proteins that specifically recognize the specific nucleic acid sequence of the marker, ribozymes, peptide nucleic acids (PNA), or other chemicals or molecules with specific affinity.
- proteins that specifically recognize the specific nucleic acid sequence of the marker ribozymes, peptide nucleic acids (PNA), or other chemicals or molecules with specific affinity.
- PNA peptide nucleic acids
- Microarray expression may be detected by scanning the microarray with a variety of laser or CCD-based scanners, and extracting features with numerous software packages, for example, IMAGENETM (Biodiscovery), Feature Extraction Software (Agilent), SCANLYZETM (Stanford Univ., Stanford, CA.), GENEPIXTM (Axon Instruments).
- the methylation is quantified with PyroMarkTMMD Pyrosequencing System (Qiagen) using PyroPyroMark® Gold Q96 Reagents (Qiagen, Cat#972804).
- PyroMarkTMMD Pyrosequencing System Qiagen
- PyroPyroMark® Gold Q96 Reagents Qiagen, Cat#972804
- Other approaches for methylation quantification include, for example, methylation specific QPCR or quantitative bisulfite sequencing of methylation.
- inhibitors that reduce the level of endogenous ARID5B in a subject.
- the term “inhibitor” refers to a compound which is capable of reducing the expression of a gene or the activity of the product of such gene to an extent sufficient to achieve a desired biological or physiological effect. Therefore, the term “inhibitor” as used herein includes one or more of an oligonucleotide inhibitor, including siRNA, shRNA, miRNA and ribozymes.
- RNA interference refers to its meaning as is generally accepted in the art.
- the term generally refers to the biological process of inhibiting, decreasing, or down-regulating gene expression in a cell, and which is mediated by short interfering nucleic acid molecules (e.g., siRNAs, miRNAs, shRNAs).
- RNA interference is meant to be equivalent to other terms used to describe sequence-specific RNA interference, such as post-transcriptional gene silencing, translational inhibition, transcriptional inhibition, or epigenetics.
- nucleic acid agents of the invention can be used to epigenetically silence ARID5B at either the post- transcriptional level or the pre-transcriptional level.
- epigenetic modulation of gene expression by nucleic acid agents of the invention can result from modification of chromatin structure or methylation patterns to alter gene expression.
- modulation of gene expression by nucleic acid agents of the invention can result from cleavage of RNA (either coding or non-coding RNA) via RISC, or via translational inhibition, as is known in the art or modulation can result from transcriptional inhibition.
- inhibitor refers to their meanings as are generally accepted in the art.
- the terms generally refer to the reduction in the (i) expression of a gene or target sequence and/or the level of RNA molecules encoding one or more proteins or protein subunits, and/or (ii) the activity of one or more proteins or protein subunits, below that observed in the absence of the single-stranded RNAi molecules of the invention.
- Down-regulation can also be associated with post-transcriptional silencing, such as RNAi-mediated cleavage, or by alteration in DNA methylation patterns or DNA chromatin structure.
- RNAi agent inhibition, down-regulation, reduction or knockdown with an RNAi agent can be in reference to an inactive molecule, an attenuated molecule, an RNAi agent with a scrambled sequence, or an RNAi agent with mismatches.
- gene silencing refers to a partial or complete loss-of-function through targeted inhibition of an endogenous target gene in a cell.
- the term is used interchangeably with RNAi, "knockdown,” “inhibition,” “down-regulation,” or “reduction” of expression of a target gene.
- nucleic acid sequence for ARID5B is known in the art, and it is within the skill of those in the art to design and produce gene silencing oligonucleotides such as siRNA using this sequence.
- siRNA that silence ARID5B are
- the disclosed methods can involve the targeted methylation of CpG sites within the ARID5B gene.
- Enzymes capable of modifying methylation status are known on the art and can be targeted to ARID5B gene to methylate the CpG sites.
- targeted DNA methylation of the CpG sites within the ARID5B gene is accomplished using a gene editing tool such as a zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), mega-nuclease, CRISPR/Cas, structure-guided endonuclease (SGN), or targetron. All of themcan achieve precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs).
- ZFN zinc finger nuclease
- TALEN transcription activator-like effector nuclease
- SGN structure-guided endonuclease
- the DSB may then be repaired by either non-homologous end joining repair system (NHEJ) or homologous recombination- based double-strand break repair pathway (HDR).
- NHEJ non-homologous end joining repair system
- HDR homologous recombination- based double-strand break repair pathway
- targeted DNA methylation of the CpG sites within the ARID5B gene is accomplished using a CRISPR system.
- Compositions and methods for making and using CRISPR-Cas systems are described in U.S. Pat. No.
- the method can involve a catalytically inactive site specific nuclease fused to an effector domain having methylation activity; and a guide sequence or a nucleic acid that encodes a guide sequence.
- the catalytically inactive site specific nuclease is a catalytically inactive Cas protein (e.g., a Cas9 protein or a Cpfl protein).
- the guide sequences may be ribonucleic acid guide sequences. In certain aspects, the guide sequence is from about 10 base pairs to about 150 base pairs in length.
- the one or more guide sequences may comprise two or more guide sequences.
- demethylation activity can be delivered to a cell or subject, e.g., by administering a nucleic acid that encodes the polypeptide, which nucleic acid may be, e.g., a viral vector or may be a translatable nucleic acid (e.g, synthetic modified mRNA.
- a nucleic acid that encodes the polypeptide which nucleic acid may be, e.g., a viral vector or may be a translatable nucleic acid (e.g, synthetic modified mRNA.
- modified mRNA examples include Warren et al. (Cell Stem Cell 7(5):618- 30, 2010, Mandal PK, Rossi DJ. Nat Protoc. 2013 8(3):568-82, US Pat. Pub. No. 20120046346 and/or WO2011/130624.
- one or more guide sequences include sequences that recognize DNA in a site-specific manner.
- guide sequences can include guide ribonucleic acid (RNA) sequences utilized by a CRISPR system or sequences within a TALEN or zinc finger system that recognize DNA in a site-specific manner.
- the guide sequences comprise a portion that is complementary to a portion of each of the one or more genomic sequences and comprise a binding site for the catalytically inactive site specific nuclease.
- the RNA sequence is referred to as guide RNA (gRNA) or single guide RNA (sgRNA).
- a single RNA sequence can be complementary to one or more (e.g., all) of the genomic sequences that are being modulated or modified.
- a single RNA is complementary to a single target genomic sequence.
- multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) RNA sequences are introduced wherein each RNA sequence is complementary to (specific for) one target genomic sequence.
- two or more, three or more, four or more, five or more, or six or more RNA sequences are complementary to (specific for) different parts of the same target sequence.
- two or more RNA sequences bind to different sequences of the same region of DNA.
- a single RNA sequence is complementary to at least two target or more (e.g., all) of the genomic sequences. It will also be apparent to those of skill in the art that the portion of the RNA sequence that is complementary to one or more of the genomic sequences and the portion of the RNA sequence that binds to the catalytically inactive site specific nuclease can be introduced as a single sequence or as 2 (or more) separate sequences into a cell, zygote, embryo or nonhuman animal. In some embodiments the sequence that binds to the catalytically inactive site specific nuclease comprises a stem-loop.
- the RNA sequence used to modify gene expression is a modified RNA sequence comprising a 5-methylcytidine (5mC).
- the RNA sequence can vary in length from about 8 base pairs (bp) to about 200 bp.
- the RNA sequence can be about 9 to about 190 bp; about 10 to about 150 bp; about 15 to about 120 bp; about 20 to about 100 bp; about 30 to about 90 bp; about 40 to about 80 bp; about 50 to about 70 bp in length.
- each genomic sequence to which each RNA sequence is complementary can also vary in size.
- the portion of each genomic sequence to which the RNA is complementary can be about 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38 39, 40, 41, 42, 43, 44, 45, 46 47, 48, 49, 50, 51, 52, 53,54, 55,
- each RNA sequence can be at least about 70%, 75%, 80%, 85%, 90%, 95%, 100%), etc.
- each RNA sequence is completely or partially identical or similar to each genomic sequence.
- each RNA sequence can differ from perfect complementarity to the portion of the genomic sequence by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. nucleotides.
- one or more RNA sequences are perfectly complementary (100%>) across at least about 10 to about 25 (e.g., about 20) nucleotides of the genomic sequence.
- the one or more RNA sequences also comprise a (one or more) binding site for a (one or more) catalytically inactive site specific nuclease.
- the catalytically inactive site specific nuclease may be a catalytically inactive
- CRISPR associated (Cas) protein upon hybridization of the one or more RNA sequences to the one or more genomic sequences, the
- the method further comprises administering one or more
- Cas proteins include Cas1, Cas2, Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CaslO, CaslOd, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, C
- the Cas nucleic acid or protein used in the methods is Cas9.
- a Cas protein e.g., a Cas9 protein
- a Cas protein may be from any of a variety of prokaryotic species.
- a particular Cas protein e.g., a particular Cas9 protein
- a Cas protein e.g., a Cas9 protein
- a Cas protein may be obtained from a bacteria or archaea or synthesized using known methods.
- a Cas protein may be from a gram positive bacteria or a gram negative bacteria.
- the Cas protein is Cpfl protein or a functional portion thereof.
- the Cas protein is Cpfl from any bacterial species or functional portion thereof.
- RNA sequences sgRNA
- DNA methylation is established by two de novo DNA methyltransferases (Dnmt3a/b), and is maintained by Dnmtl.
- the method can further comprise introducing other molecules or factors into the cell to facilitate methylation of the genomic sequence.
- An agent that enhances DNA methylation may be an inhibitor of an endogenous DNA demethylase.
- Sequence-specific nucleases have been developed to increase the efficiency of gene targeting or genome editing in animal and plant systems.
- ZFNs zinc finger nucleases
- TALENs transcription activator- 1 ike effector nucleases
- ZFNs zinc finger nucleases
- TALENs transcription activator- 1 ike effector nucleases
- a pair of ZFNs or TALENs can be introduced to generate double strand breaks (DSBs), which activate the DNA repair systems and significantly increase the frequency of both
- NHEJ nonhomologous end joining
- HR homologous recombination
- compositions disclosed can be used therapeutically in combination with a pharmaceutically acceptable carrier.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
- the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
- compositions can be formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids.
- buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids.
- DsiRNA agent with cationic lipids can be used to facilitate
- cationic lipids such as lipofectin (U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (published PCT International Application WO
- Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.
- compositions typically include the nucleic acid molecule and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
- a pharmaceutical composition is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents;
- antibacterial agents such as benzyl alcohol or methyl parabens
- antioxidants such as ascorbic acid or sodium bisulfite
- chelating agents such as
- ethylenediaminetetraacetic acid ethylenediaminetetraacetic acid
- buffers such as acetates, citrates or phosphates
- agents for the adjustment of tonicity such as sodium chloride or dextrose.
- pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline,
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a
- dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
- sterile powders for the preparation of sterile injectable solutions the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier.
- the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules.
- Oral compositions can also be prepared using a fluid carrier for use as a mouthwash.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate or Sterotes
- a glidant such as colloidal silicon dioxide
- compositions are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- the compounds can also be administered by a method suitable for administration of nucleic acid agents, such as a DNA vaccine.
- nucleic acid agents such as a DNA vaccine.
- methods include gene guns, bio injectors, skin patches, micro-particle DNA vaccine technology, transdermal needle-free vaccination, intranasal delivery, and
- the disclosed compositions are prepared with carriers that will protect the nucleic acids against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
- Such formulations can be prepared using standard techniques.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.
- a therapeutically effective amount of a nucleic acid molecule depends on the nucleic acid selected. For instance, if a plasmid encoding an siRNA agent is selected, single dose amounts in the range of approximately 1 pg to 1000 mg may be administered; in some embodiments, 10, 30, 100, or 1000 pg, or 10, 30, 100, or 1000 ng, or 10, 30, 100, or 1000 g, or 10, 30, 100, or 1000 mg may be administered. In some embodiments, 1- 5 g of the compositions can be administered. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day.
- treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.
- the nucleic acid molecules of the invention can be inserted into expression constructs, e.g., viral vectors, retroviral vectors, expression cassettes, or plasmid viral vectors, e.g., using methods known in the art, including but not limited to those described in Xia et al., (2002), supra.
- Expression constructs can be delivered to a subject by, for example, inhalation, orally, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al.
- the pharmaceutical preparation of the delivery vector can include the vector in an acceptable diluent, or can comprise a slow release matrix in which the delivery vehicle is imbedded.
- the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
- the expression constructs may be constructs suitable for use in the appropriate expression system and include, but are not limited to retroviral vectors, linear expression cassettes, plasmids and viral or virally-derived vectors, as known in the art.
- Such expression constructs may include one or more inducible promoters, RNA Pol III promoter systems such as U6 snRNA promoters or H1 RNA polymerase III promoters, or other promoters known in the art.
- the constructs can include one or both strands of the siRNA. Expression constructs expressing both strands can also include loop structures linking both strands, or each strand can be separately transcribed from separate promoters within the same construct.
- compositions of this invention can be administered by means known in the art such as by parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
- the pharmaceutical compositions are administered by intravenous or intraparenteral infusion or injection.
- a suitable dosage unit of nucleic acid agent will be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day.
- Pharmaceutical composition comprising the nucleic acid agent can be administered once daily. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In that case, the nucleic acid agent contained in each sub-dose must be
- the dosage unit can also be compounded for a single dose over several days, e.g., using a conventional sustained release formulation which provides sustained and consistent release of the nucleic acid agent over a several day period. Sustained release formulations are well known in the art. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose. Regardless of the formulation, the pharmaceutical composition must contain nucleic acid agent in a quantity sufficient to inhibit expression of the target gene in the animal or human being treated. The nucleic acid agent can be compounded in such a way that the sum of the multiple units of dsRNA together contain a sufficient dose.
- Data can be obtained from cell culture assays and animal studies to formulate a suitable dosage range for humans.
- the dosage of compositions of the invention lies within a range of circulating concentrations that include the ED50 (as determined by known methods) with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels of dsRNA in plasma may be measured by standard methods, for example, by high performance liquid chromatography.
- compositions can be included in a kit, container, pack, or dispenser together with instructions for administration.
- the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) inflammatory disease or disorders.
- Subjects at risk for the disease can be identified by, for example, one or a
- a prophylactic agent can occur prior to the detection of or the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression.
- Another aspect of the invention pertains to methods of treating subjects therapeutically, i.e., altering the onset of symptoms of the disease or disorder.
- “Pharmacogenomics” refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or “drug response genotype”).
- a patient's drug response phenotype or “drug response genotype”
- Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.
- Example 1 Blood Monocyte Transcriptome and Epigenome Analyses Reveal Loci Associated with Human Atherosclerosis.
- CVD cardiovascular disease
- Monocytes and their derived macrophages are key players in inflammation that contribute to the development of many chronic diseases, including atherosclerosis (Lessner, S.M., et al. Am. J. Pathol. 160:2145-2155 (2002); Osterud, B. & Bjorklid, E. Physiol Rev. 83:1069-1112 (2003); Hansson, G.K. N. Engl. J. Med. 352:1685-1695 (2005); Ley, K., et al. Arterioscler. Thromb. Vase. Biol. 31:1506-1516 (2011)).
- the present analyses are primarily based on data collected at MESA exam 5 with concurrent analyses of purified monocyte samples of 1 ,264 randomly selected MESA participants from four MESA sites [John Hopkins University (JHU); Columbia University (CO); University of Minnesota (UMN); Wake Forest University (WFU)].
- the study protocol was approved by Institutional Review Boards of the four institutions. All participants signed informed consent.
- carotid IMT focal abnormal wall thickness
- focal thickening >50% of the surrounding IMT, as reported previously (Stein, J.H. et al. J Am Soc Echocardiogr. 21:93-111 (2008); Touboul, P.J. et al. Cerebrovasc. Dis. 23:75-80 (2007)). Presence or absence of plaque acoustic shadowing was recorded. A total plaque score (range 0-12) was calculated to describe carotid plaque burden.
- Weight was measured with a Detecto Platform Balance Scale to the nearest 0.5 kg. Height was measured with a stadiometer (Accu-Hite Measure Device with level bubble) to the nearest 0.1 cm.
- Body-mass index (BMI) was defined as weight in kilograms divided by square of height in meters.
- Type II diabetes mellitus (T2D) was defined as fasting glucose ⁇ 7.0 mmol L 1 (> 126 mg/dL) or use of hypoglycemic medication, and impaired fasting glucose was defined as fasting glucose 5.6-6.9 mmol L 1 (100-125 mg dL 1 ).
- Plasma IL-6 was measured by ultra-sensitive ELISA (Quantikine HS Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN).
- Plasma C-reactive protein was measured using the BNII nephelometer (High Sensitivity CRP; Dade Behring Inc., Deerfield, IL). Resting blood pressure was measured three times in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, FL). The average of the last two measurements was used in analysis. Hypertension was defined as systolic pressure greater than or equal to 140 mm Hg, diastolic pressure greater than or equal to 90 mm Hg or current use of anti-hypertensive medication.
- SNPs single nucleotide polymorphisms
- EDTA ethylenediaminetetraacetic acid
- DNA and RNA were isolated from samples simultaneously using the AllPrep DNA/RNA Mini Kit (Qiagen, Inc., Hilden, Germany).
- DNA and RNA QC metrics included optical density (OD) measurements, using a NanoDrop spectrophotometer and evaluation of the integrity of 18 s and 28 s ribosomal RNA using the Agilent 2100 Bioanalyzer with RNA 6000 Nano chips (Agilent Technology, Inc., Santa Clara, CA) following manufacturer's instructions.
- RNA with RIN (RNA Integrity) scores > 9.0 was used for global expression microarrays. The median of RIN for our 1,264 samples was 9.9.
- Multidimensional scaling plots showed the five common control samples were highly clustered together and identified three outlier samples, which were excluded subsequently.
- the lllumina HumanHT-12 v4 Expression BeadChip included >47,000 probes for >30,000 genes (with unique Entrez gene IDs).
- Statistical analyses excluded probes with non-detectable expression in >90% of MESA samples (using a detection p-value cut-off of 0.0001), probes overlapping repetitive elements or regions, probes with low variance across the samples ( ⁇ 10th percentile), or probes targeting putative and/or not well-characterized genes, i.e. gene names starting with KIAA, FI_J, HS, MGC, or LOG, 14,619 mRNA transcripts from 10,989 unique genes were included in the analyses of the presented manuscript.
- the lllumina HumanMethylation450 BeadChip included probes for 485K CpG sites. Exclusion criteria included probes with "detected" methylation levels in ⁇ 90% of MESA samples using a detection p-value cut-off of 0.05 and 65 control probes which assay highly-polymorphic single nucleotide polymorphisms (SNPs) rather than DNA methylation (Pidsley, R. et al. BMC Genomics 14:293 (2013)). Methylation data for the total of 484,817 CpG sites were included in the analyses.
- SNPs single nucleotide polymorphisms
- RNA sequencing A subset of 374 samples was randomly selected from the 1 ,264 MESA monocyte samples for RNA sequencing.
- Total RNA samples were enriched for mRNA, by depleting rRNA using the MICROBExpress kit from Ambion and following the manufacturer's instructions.
- Poly(A) mRNA was enriched, and lllumina compatible, strand-specific libraries were constructed using lllumina's TruSeq
- Stranded mRNA HT Sample Prep Kit (lllumina, RS-122-2103). 1 of total RNA with RIN ⁇ 8.0 was converted into a library of stranded template molecules suitable for subsequent cluster generation and sequencing by lllumina HiSeq. The libraries generated were validated using Agilent 2100 Bioanalyzer and quantitated using Quant-iT dsDNA HS Kit (Invitrogen) and qPCR. Six individually indexed cDNA libraries were pooled and sequenced on lllumina HiSeq, resulting in an average of close to 30 million reads per sample.
- lllumina sequencing runs were processed to de-multiplex samples and generate FastQ files using the lllumina provided configureBclToFastq.pl script to automate running CASAVA 1.8.4 using default parameters for removal of sequencing reads failing the chastity filter (yes) and mismatches in the barcode read (0).
- T s is the normalized total count of sample s, using the Trimmed Mean of M-values (TMM) normalization method (Robinson, M.D. & Oshlack, A. Genome Biol. 11:R25 (2010)) as
- a subset of 90 samples was selected from the 1 ,264 MESA monocyte samples, based on carotid plaque score extremes, matched for age, sex, and race. Genomic DNA from monocytes was bisulfite modified using the EZ DNA
- the Weighted Gene Co-Expression Network Analysis (WGCNA) method was used to construct network modules of highly correlated transcripts, using the R package WGCNA (Langfelder, P. & Horvath, S. BMC. Bioinformatics. 9:559 (2008)).
- a total of 1 ,261 MESA samples were included in the co-expression network analysis after removing three outlier samples based on hierarchical clustering, and 13,196 mRNA transcripts were included.
- an unsigned weighted network was constructed based on the pairwise correlations among all transcripts considered, using a soft thresholding power of 5, chosen to produce approximately a scale-free topology. Then, using the topological overlap measure to estimate the network interconnectedness, the transcripts were hierarchically clustered.
- WGCNA produces a set of modules, each containing a unique set of mRNA transcripts.
- the module eigengene was obtained to represent each module, which corresponds to the first eigenvector of the within-module expression correlation matrix (or the first right-singular vector of the standardized within-module expression matrix).
- the overall goal of the association analysis was to characterize the associations of each measure of atherosclerosis (carotid plaque and CAC) with each of genome-wide measures of mRNA expression and DNA methylation.
- Analyses were performed using the linear model (Im) function of the Stats package and the stepAIC function of the MASS package in R.
- Reported correlations (r) represent the partial Pearson product-moment correlation coefficient.
- M-values genome-wide DNA methylation profiles.
- the M-value is well suited for high-level analyses and can be transformed into the beta-value, an estimate of the percent methylation of an individual CpG site that ranges from 0 to 1 (M is logit(beta-value)).
- P-values were adjusted for multiple testing using the q-value FDR method (Storey, J.D. & Tibshirani, R. Proc. Natl. Acad. Sci. U. S. A 100:9440- 9445 (2003)) and Benjamini Hochberg FDR (Benjamini, Y. & Hochberg, Y. Journal of the Royal Statistical Society B 57:289-300 (2006)) when applicable.
- a first approach consists of computing robust standard errors (SE) by sandwich-type covariance matrices and scaled test statistics, in particular the Satorra-Bentler statistic whose amount of rescaling reflects the degree of kurtosis, while the second approach uses specific bootstrapping methods to obtain both SE and test statistics (Rosseel, Y. Journal of Statistical Software 48:1-36 (2012)). The reported results are based on bootstrapping which were found to be somewhat more conservative than the use of robust SE and the Satorra-Bentler statistic.
- SE standard errors
- CpGs with methylation significantly associated with carotid plaque scores or CAC were investigated for association with cis-gene expression by performing a look-up in the results from our previous analysis (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)) of the same samples. Briefly, to identify DNA methylation associated with gene expression in cis, separate linear regression models were fit with the M-value for each CpG site (adjusted for methylation chip and position effects) as a predictor of transcript expression for any autosomal gene within 1 Mb of the CpG in question. Covariates were age, sex, and race/ethnicity, and study site.
- mRNA expression and DNA methylation of the most significantly associated mRNA and CpGs associated with carotid plaques scores and CAC were also investigated for association with nearby genetic variants.
- Covariates were age, sex, and race/ethnicity, and study site.
- Separate linear regression models were fit with single nucleotide polymorphisms (SNPs) located within 1 Mb as a predictor of the mRNA expression (log2 transformed) or the methylation (M-value) in the MESA samples from Caucasian participants, including SNPs with a minor allele frequency > 0.05 in the MESA Caucasian population.
- P- values were adjusted for multiple testing using the q-value FDR method (Storey, J.D. & Tibshirani, R. Proc. Natl. Acad. Sci. U. S. A 100:9440-9445 (2003)).
- Ingenuity® Pathway Analysis (I PA®, QIAGEN Redwood City) was used to examine the enrichment of canonical pathways and bio-functions.
- In silico functional prediction of chromatin states in monocytes was performed using ChromHMM (Ernst, J. & Kellis, M. Nat Methods 9:215-216 (2012)) to predict segmentation among six states, based on histone modifications in monocyte samples from the BLUEPRINTproject (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al.
- H3K27ac H3K4me1, H3K4me3
- ENCODE Rosenbloom, K.R. et al. Nucleic Acids Res. 41:D56-D63 (2013)
- H3K36me3 Other functional information utilized includes DNase hypersensitive hotspot data in a monocyte sample
- Hi-C data in a B-cell line (GM12878) (Rao, S.S. et al. Cell 159:1665-1680 (2014); Dixon, J.R. et al. Nature 485:376-380 (2012); Heidari, N. et al. Genome Res 24:1905-1917 (2014); Dixon, J.R. et al. Nature 518:331-336 (2015)), including the contact matrix heatmap and virtual 4C results were adapted from the YUE lab Hi-C Interactions and Virtual 4C website.
- transcriptomic profiling was performed using the lllumina HumanHT-12 v4 Expression BeadChip, and ARID5B mRNA expression measured by qPCR.
- Human monocytic THP-1 cell line was purchased from the American Tissue Culture Collection (ATCC). Cells were maintained in complete RPMI 1640 medium (Invitrogen) supplemented with 100 units ml 1 of penicillin, 100 ug ml 1 of
- siRNA ID: S38579 designated as siARID5B1
- siARIDSB 2 siRNA ID: s38580
- siARIDSB 1 siARID5B 1
- siRNA transfection was performed using THP1 monocytes that were split 24h prior to transfection.
- 10nM of siARIDSB were electronically transfected into THP-1 cells for 24 h and 48h using Amaxa® Human Monocyte Nucleofector Kit and an Amaxa nucleofector II device (Lonza, Inc.). Scrambled siRNAs were transfected as negative controls. Samples were incubated for 24 h, followed by 3 h of LPS (LPS: 100 ng ml 1 ) stimulation.
- cytokines in human monocytic THP-1 cells presented in Fig. 10 were measured by quantitative real-time RT-PCR using gene-specific TaqMan probe sets in an ABI prism 7000 sequence detection system (life technologies). GAPDH mRNA was the internal loading control.
- the plates were incubated at 37°C in 5% CO2 for 24 h and cells that had migrated into the lower chamber were counted using cell countess.
- Genome-wide gene expression and DNA methylation data has been deposited in the NCBI Gene Expression Omnibus (GEO) and is accessible through GEO Series accession number GSE56047 and GSE56046, respectively.
- GEO NCBI Gene Expression Omnibus
- the Multi-Ethnic Study of Atherosclerosis is a multi-site, longitudinal study designed to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease in a population cohort of 6,814 participants. Since its inception in 2000, five clinic visits have collected extensive clinical, socio- demographic, lifestyle, behavior, laboratory, nutrition, and medication data (Bild, D.E. et al. Am. J. Epidemiol. 156:871-881 (2002)). At Exam 5, carotid ultrasound and computed tomography (CT), were used to quantify carotid plaque burden (carotid plaque score, range 0-12) and coronary artery calcification (CAC Agatston score), respectively.
- CT computed tomography
- BMI body- mass index
- HDL-C and LDL-C high- and low- density lipoprotein cholesterol
- T2DM type II diabetes mellitus
- the transcriptome and methylome of monocytes purified at MESA Exam 5 were profiled concurrently. In a separate effort to evaluate reproducibility of single-time measures, there was a high consistency of repeated lllumina microarray data over five months (Fig. 7), suggesting both RNA expression and DNA methylation at most loci can be stable over time in
- WBC white blood cell
- CD14+CD16+ cells was associated with the measures of atherosclerosis.
- ARID5B plays a key metabolic role in adipose, liver and smooth muscle, and was previously implicated in lipid metabolism and adipogenesis in mice (Whitson, R.H., et al. Biochem. Biophys. Res Commun.
- PDLIM7 is an actin and protein kinase adaptor that promotes mineralization, which might be relevant to plaques with calcium.
- CMTN eigengene (the first principal component) of CMTN is associated with a transcriptional profile expected to increase intracellular cholesterol, including up- regulation of cholesterol uptake (LDLR and MYLIP) and cholesterol and fatty acid synthesis genes (HMGCS1, FDFT1, SQLE, CYP51A1, SC4MOL, SC5DL, SCD and FADS1), as well as down-regulation of cholesterol efflux genes (ABCG1 and
- the 37 differentially methylated sites associated with carotid plaque or CAC presented higher variable CpG methylation levels (across MESA population) with the interdecile range (IDR) of the percentage of methylation (measured by beta- value (Du, P. et al.
- the SC4MOL eMS resides in a predicted weak promoter region of a B cell line; however, this region was identified as heterochromatin in monocytes (using ChromHMM (Ernst, J. & Kellis, M. Nat Methods 9:215-216 (2012)) for histone modification data from BLUEPRINT (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al. Science 345:1251086 (2014)), Fig. 8, Table 5 and Table 7).
- BLUEPRINT monocyte data Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al.
- Atherosclerosis-associated genomic features eight mRNA (Table 8) and 33 CpGs (Table 9) were also associated with one or more traditional CVD risk factors, particularly demographics (age, sex, race/ethnicity), cigarette smoking, and obesity.
- CVD risk factors particularly demographics (age, sex, race/ethnicity), cigarette smoking, and obesity.
- Table 6 and Table 9 the predicted effects of the majority of CVD risk factors on atherosclerosis that were mediated through the genomic features have the similar direction as the observed associations between the CVD risk factors and the measure of atherosclerosis.
- the ARID5B mRNA and cg25953130 methylation associations with carotid plaque and CAC were not significant in T cell samples (p>0.05), but remained statistically significant (p ranges from 3.8x10 3 to 7.2x10 3 ) when analyzed in the monocyte samples from the same subset.
- hypomethylation is a well-known, robust biomarker of smoking that is linked to carotid plaque score in MESA (Reynolds, L.M. et al. Circ Cardiovasc. Genet 8:707-716 (2015)). These results demonstrate examples of both potential cell-type specific and shared genomic features in relation to burden of atherosclerosis.
- ARID5B mRNA knockdown efficiency was 85% and 76% in the two experiments (Fig. 9); both consistently showed that ARID5B knockdown decreased expression of 1,320 genes and increased expression of 1 ,162 genes (FDR ⁇ 0.005 in the discovery set and FDR ⁇ 0.05 in the replication set).
- the 2,482 ARID5B-modified genes displayed a significant overrepresentation of related pathways including inflammatory/immune response, chemotaxis, migration, extravasation signaling, and phagocytosis, and also the lipid synthesis functional pathway, compared to the background list of genes detectable on the array (enrichment FDR ⁇ 0.05, Figure 5A, full list of genes provided in Table 10).
- Enriched bio-functions and canonical pathways in the inflammatory response pathway consisted of mainly down-regulated genes, including key proinflammatory cytokines (e.g. TNF, IL1a), activator and effector cytokines from the type I interferon signaling pathway (e.g. IRF3, IFNB1 , STAT1 and STAT2), and antigen processing and presentation genes (e.g. HC class II cell surface receptors: HLA-DRA, and HLA-DRBs, Fig. 9, bolded in Table 10), collectively indicating decreased pathway activation.
- proinflammatory cytokines e.g. TNF, IL1a
- activator and effector cytokines from the type I interferon signaling pathway e.g. IRF3, IFNB1 , STAT1 and STAT2
- antigen processing and presentation genes e.g. HC class II cell surface receptors: HLA-DRA, and HLA-DRBs, Fig. 9, bolded in Table 10
- ARID5B knockdown experiment was repeated and ELISA assays of culture media performed for IL1A, the pro-inflammatory cytokine that was most significantly reduced by ARID5B mRNA knockdown (FDR: 3.79x10 "8 , 4.48x10 -4 in the first two experiments).
- Figure 11A gives the odds ratio of type II diabetes (T2DM) according to ARID5B levels after prior stratification of persons according to their overweigh and obesity status, the strongest risk factor for T2DM.
- Tertiles of ARID5B were used in these analyses to ensure an adequate representation of ARID5B levels for all strata under investigation.
- the ARID5B tertiles showed a strong effect in overweight and obesity subgroups, subjects with diabetes more frequently had ARID5B values in the medium and highest tertile (Odds ratio for obese subjects with the highest tertile of ARID5B was 11 , compared to those with normal weight and the lowest tertile of ARID5B, p values: 1.1 E-6)
- Figure 11 B showed the mean carotid plaque scores (log transformed) according to ARID5B levels after prior stratification of persons according to their impaired glucose tolerance and diabetes status, one of the strongest risk factors for atherosclerotic CVD.
- the ARID5B tertiles showed a significant (p ⁇ 0.001) effect at normal, impaired glucose tolerance, and diabetes subgroups).
- ARID5B significantly improves the risk stratifications for both T2DM and atherosclerosis, above and beyond their known risk factors.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Disclosed herein are compositions and methods for diagnosing and treating inflammatory diseases based on the disclosed overexpression and hypomethylation of ARID5B that is associated with an increased risk of inflammatory disease. Therefore, methods are disclosed that involve assaying samples from subjects for ARID5B gene expression, or for methylation of an ARID5B CpG site that is negatively correlated with ARID5B gene expression. Also disclosed are methods that involves administering to the subject a composition comprising an ARID5B inhibitor in an amount effective to reduce endogenous expression levels of ARID5B in the subject.
Description
ARID5B OVEREXPRESSION IN INFLAMMATORY DISEASES
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of U.S. Provisional Application No. 62/488,320, filed April 21, 2017, which is hereby incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
This invention was made with Government Support under Grant No.
HL101250 and HL135009 awarded by the National Institutes of Health. The
Government has certain rights in the invention.
BACKGROUND
Despite improvements in prevention and therapy of atherosclerotic
cardiovascular disease (CVD), it remains to be the leading cause of death in the developed world. Although traditional risk factors for atherosclerosis are established, there is substantial unexplained variation in the atherosclerosis phenotype. Most acute coronary syndromes and ischemic strokes are caused by rupture-prone vulnerable plaques, however, the risk factors for plaque vulnerability are largely unknown. Genome-wide association studies (GWAS) have identified a number of susceptibility variants for CVD; however, they explain only a small percent of CVD risk. The available therapies continue to primarily target hyperlipidemia and prevention of thrombosis. To develop effective therapeutic approaches for primary and secondary CVD prevention, a better understanding of the molecular mechanisms and pathophysiology of the disease is needed.
SUMMARY
Disclosed herein are compositions and methods for diagnosing and treating inflammatory diseases based on the disclosed overexpression and hypomethylation of ARID5B that is associated with an increased risk of inflammatory disease.
Therefore, a method is disclosed that involves obtaining a sample from a subject, such as a subject having or suspected of having an inflammatory disease, and assaying the sample for ARID5B gene expression, or for methylation of an ARID5B CpG site that is negatively correlated with ARID5B gene expression.
In some embodiments, the CpG methylation site is one or more of the underlined CpG site found in the nucleic acid sequence:
ATAAATATTYGGTGTTATAATAGAGTAGTAATTAAATGGAAATTTTAATATA ATTGTTAATAGTAGTAAGAATTGGAATAGYGTTAGGTATATAAAGTTGATGTTTTG TYGTTGGTTGGTTGTTAGGAGTATAGTGA (SEQ ID NO:1). For example, the CpG methylation site can be cg25953130.
Also disclosed is a method for diagnosing or prognosing an inflammatory disease in a subject that involves assaying a sample from the subject for ARID5B expression levels, wherein detection of elevated ARID5B expression levels compared to a control is an indication that the subject has an inflammatory disease. Since methylation of the disclosed ARID5B CpG sites negatively correlate with ARID5B gene expression, in some embodiments, ARID5B expression levels are assayed by assaying for methylation of the ARID5B CpG sites.
The inflammatory disease of the disclosed methods can be selected from the group comprising diabetes mellitus type 2 or a cardiovascular diseases (e.g.
atherosclerosis or stroke).
Also disclosed is a method for treating an inflammatory disease in a subject that involves obtaining a sample from a subject having or suspected of having an inflammatory disease, assaying the sample for ARID5B expression levels, and treating the subject for an inflammatory disease if the ARID5B expression levels are elevated compared to a control.
For example, in some embodiments the subject presents with a high risk for cardiovascular diseases (CVD), e.g. based on family history, obesity, diabetes, hyperlipidemia, hypertension, or prior incidence of CVD. In these embodiments, the subject can be treated for CVD if ARID5B expression levels are elevated. Treatment for cardiovascular disease include lifestyle changes (e.g. diet and exercise), statins, and/or blood thinners. In some embodiments, the subject is treated with an antiinflammatory agent \f ARID5B expression levels are elevated.
In some cases, the choice of treatment is based on the level of ARID5B expression. In particular, the disclosed methods use ARID5B expression levels to stratify subjects based on disease risk. Subjects determined to be at higher risk based on elevated ARID5B expression can be treated with standard of care for that risk, including the use of aggressive treatments earlier than would otherwise be used. For example, all subjects with CVD should be recommended lifestyle modification. As ARID5B levels elevate, the subject can be treated with a statin. As levels elevate further, the subject can be further treated with ezetimibe and/or PCSK9 inhibitors. As levels elevate even further, the subject can be further treated with a PCSK9 antibody.
In some embodiments the subject presents with a high risk for diabetes or pre-diabetes, e.g. based on family history, weight, blood glucose levels, and/or prior incidence of diabetes. In these embodiments, the subject is treated for diabetes or pre-diabetes if ARID5B expression levels are elevated. Treatment for diabetes include lifestyle changes (diet and exercise), metformin, insulin, sulfonylurea, GLP-1 agonists, thiazolidinedione, glinide, SGLT2 inhibitors, DDP-4 inhibitorss, alpha- glucosidase inhibitors, and pramlintide. In some embodiments, the subject is treated with an anti-inflammatory agent \ ARID5B expression levels are elevated. In some cases, the choice of treatment is based on the level of ARID5B expression.
In some embodiments, ARID5B expression levels are used to screen subjects for the presence or risk of an inflammatory disease, such as CVD or diabetes, before the subject presents with any clinical symptoms. In these embodiments, detection of elevated ARID5B expression levels can be an indication that the subject should be screened for an inflammatory disease, such as CVD or diabetes. In some cases, the subject is directed to make lifestyle changes (e.g. diet and exercise) to reduce the risk of disease onset. In some cases, the subject is treated prophylactically with antiinflammatory agents to prevent the onset of an inflammatory disease. In some cases, the subject is treated using standards of care for CVD and/or diabetes prevention, e.g. statins.
Also disclosed is a method of treating a subject with elevated ARID5B expression levels that involves administering to the subject an anti-inflammatory agent. For example, in some embodiments, the subject having elevated ARID5B expression levels is treated with an anti-IL6 drug, such as tocilizumab (Actemra), siltuximab (Sylvant), Sarilumab, clazakizumab, olokizumab (CDP6038), elsilimomab, BMS-945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ARGX-109, FE301, and FM101.
Also disclosed is a method for treating a subject with an inflammatory disease that involves administering to the subject a composition comprising an ARID5B inhibitor in an amount effective to reduce endogenous expression levels of ARID5B in the subject.
In some embodiments, the ARID5B inhibitor is a gene silencing agent. As an example, the gene silencing agent can be an antisense oligonucleotide, siRNA, or shRNA. In some embodiments, the ARID5B inhibitor is a CRISPR-Cas system that methylates a disclosed ARID5B CpG site that negatively correlates with ARID5B gene expression. In some embodiments, prior to treatment, the method further comprises detecting elevated ARID5B expression levels in a sample from the
subject. Since methylation of the disclosed ARID5B CpG sites negatively correlate with ARID5B gene expression, in some embodiments, ARID5B expression levels are assayed by assaying for methylation of the ARID5B CpG sites.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
DESCRIPTION OF DRAWINGS
Figure 1. Transcriptomic associations with Carotid Plaque and CAC Scores in 1 ,208 MESA participants. The two volcano plots showing effect size (β) of -logl 0(p- value) for associations of each mRNA expression (for 10,989 unique mRNA expression) with A) carotid plaque score and B) CAC. The red line illustrates the threshold for an FDR<0.05 (linear regression adjusting for age, sex, race, and study site). Expression of ARID5B and PDLIM7 (bolded) were associated with both carotid plaque and CAC score; green star indicates mRNA expression most significantly associated with carotid plaque or CAC. The two forest plots showing the direction and effect size (β) for associations of each mRNA expression (in Panel A and B) with C) carotid plaque score and D) CAC score in the full model (including traditional CVD risk factors), overall and by the two independent studies (study 1 : JHU + CO, red; study 2: UMN + WFU, blue); φ significantly different effect sizes observed by study (pinteraction<0.05). E) The forest plot showing ARID5B mRNA expression
associations with carotid plaque, stratified by age (<65 years and >65 years), sex, ethnicity/race, CVD and statin use.
Figure 2. Methylomic associations with Carotid Plaque and CAC Scores in 1,208 MESA participants. The two Manhattan plots showing chromosomal locations of -loglO(p-value) for associations of each CpG site (for 484,817 CpG sites) with A) carotid plaque score and B) CAC score. The red line illustrates the threshold for an FDR≤0.05; linear regression adjusting for age, sex, race, and study site). One CpG at ILVBL (bolded, green dot) was associated with both carotid plaque and CAC; green star indicates CpGs most significantly associated with carotid plaque or CAC.
Notably, for ARID5B, both methylation (cg25953130, green dot) and mRNA expression were significantly associated with carotid plaque score. The two forest plots showing the direction and effect size (β) for associations of each CpG sites (in Panel A and B, the most significant association at each unique loci is shown) with C) Carotid plaque score and D) CAC in the full model (including traditional CVD risk factors), overall and by the two independent studies (study 1 : JHU + CO, red; study
2: UMN + WFU, blue);† significantly different effect sizes observed by study
(pinteraction<0.05). E) The forest plot showing ARID5B cg25953130 methylation associations with carotid plaque score, stratified by age (<65 years and >65 years), sex, ethnicity/race, CVD and statin use.
Figure 3. In vivo and in silico functional analysis of ARID5B CpG cg25953130
A) ARID5B mRNA expression (y-axis; normalized value) is significantly negatively correlated (Pearson r) with methylation of a CpG (cg25953130) in 1,264 CD14+ samples from MESA participants. B) A regional association plot of ARID5B CpG methylation with carotid plaque score in MESA (y-axis: -Iog10 (p-value), x-axis:
position on chromosome (chr) 10) is shown in the top panel; the bottom panel shows the ARID5B expression-associated CpG (cg25953130, chrl 0:63,753,550, hg19, indicated by the light blue line) located in an ARID5B intron, overlaps a DNase hypersensitive site in a CD14+ sample from BLUEPRINT, histone marks indicative of a strong enhancer/promoter in a CD14+ and B cell line sample from BLUEPRINT and ENCODE (see Supplementary Fig. 3 for ChromHMM color code), as well as a transcription factor binding site for EP300, detected in a neuroblastoma cell line (SK- N-SH_RA). C) A physical interaction is detected between the ARID5B promoter and the region near the ARID5B CpG cg25953130 by both HiC and ChlA-PET data. The heatmap (white, low; red, high; top panel) graphically displays Hi-C interaction counts (the normalized number of contacts between a pair of loci) for the large region surrounding ARID5B in a B cell line (GM12878; reported by Rao et al. 2014); active enhancer marks (H3K27ac and H3K4me1 in GM12878 from ENCODE) are shown below; the bottom panel zooms in on ARID5B (blue highlighted region) Hi-C interaction. There were 1937 contacts between the ARID5B promoter and the cg25953130 region. Below the Hi-C interaction is a depiction of detected ChlA-PET interactions (Chromatin Interaction Analysis by Paired-End Tag sequencing) for the region flanking ARID5B in the B cell line (GM12878; reported by Heidari et al. 2015), represented by blue curves.
Figure 4. ARID5B expression and methylation are associated with subclinical and clinical CVD risk. Odds ratio of subclinical and clinical CVD (in the full model with adjustment of traditional CVD risk factors and statin use) by tertiles of A) ARID5B mRNA expression and B) ARID5B methylation (cg25953130).
Figure 5. siRNA Knockdown of ARID5B alters immune/inflammatory response and lipid metabolism genes. After 3 h of LPS treatment (100 ng ml-1) of THP1- monocyte ARID5B knockdown samples compared to control samples (scrambled siRNA), A) the transcriptome (N=8 per group) were enriched with the inflammatory
response genes including the listed bio-functions and canonical pathways
(enrichment FDR<0.05 from IRA); proportion of genes upregulated shown as red, downregulated shown as blue. B) Relative IL1A levels (mean ± standard deviation) of mRNA expression in cells (n=3 per group, by RT-PCR) and protein expression in culture media (n=3 per group, by ELISA) decreased. C) Cell migration (mean ± standard deviation, n=10 and 4 per group in experiment 1 and 2, respectively), and phagocytosis (mean ± standard deviation, n=8, 4, and 4 per group in experiment 1 , 2, and 3, respectively) were inhibited.
Figures 6A and 6B. Histograms of subclinical CVD phenotypes.
Figures 7A to 7D. Reproducibility of Microarray mRNA Expression and DNA
Methylomic Data Overtime. A) Correlation of the repeated measurements of transcriptomic profiles for one subject between two visits 5-month apart; B) correlation of transcriptomic profiles between two subjects at visit 1 ; C) Correlation of the repeated measurements of methylomic profiles for one subject between two visits 5-month apart; D) correlation of methylomic profiles between two subjects at visit 1.
Figure 8. Chromatin Map of Monocytes. Six chromatin states (top panel) predicted using ChromHMM and four CD14+ histone marks (from BLUEPRINT) are enriched with various genomic features (middle panel); annotation of the six chromatin states is provided (bottom panel).
Figures 9A and 9B. siRNA Knockdown of ARID5B alters
immune/inflammatory response and lipid metabolism genes. A) Relative ARID5B mRNA expression levels in human THP1 -monocytes after treatment with two ARID5B siRNA individually, and in combination. Levels shown are the average (±S.E.M.). After 3 h of LPS treatment (100 ng ml-1), the THP1-monocyte transcriptome in 8 ARID5B knockdown samples compared to 8 control samples (scrambled siRNA) were enriched with inflammatory response genes; B) heatmap shows mRNA expression of selected key inflammatory response genes (including cytokine, interferon signaling, and antigen processing and presentation genes) in the 8 scrambled siRNA samples compared to 8 siARID5B samples.
Figures 10A and 10B. Time Course of LPS-induced TNF and IL1A Gene
Expression in Human THP1 monocytes. Gene expression of (A) TNF and (B) IL1A, in LPS (100 ng/ml) stimulated THP1 cells.
Figures 11A and 11B are bar graphs showing diabetes (Fig. 11A) and subclinical CVD (Fig. 11B) risk as a function of ARID5B expression with
overweigh/obesity or impaired glucose tolerance/diabetes status.
DETAILED DESCRIPTION
The disclosed subject matter can be understood more readily by reference to the following detailed description, the Figures, and the examples included herein.
Before the present disclosure is described in greater detail, it is to be understood that this disclosure is not limited to particular embodiments described, and as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, the preferred methods and materials are now described.
All publications and patents cited in this specification are cited to disclose and describe the methods and/or materials in connection with which the publications are cited. All such publications and patents are herein incorporated by references as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. Such incorporation by reference is expressly limited to the methods and/or materials described in the cited publications and patents and does not extend to any lexicographical definitions from the cited publications and patents. Any lexicographical definition in the publications and patents cited that is not also expressly repeated in the instant application should not be treated as such and should not be read as defining any terms appearing in the accompanying claims. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided could be different from the actual publication dates that may need to be
independently confirmed. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.
It is understood that the disclosed methods and systems are not limited to the particular methodology, protocols, and systems described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
Definitions
Unless otherwise expressly stated, it is in no way intended that any method or aspect set forth herein be construed as requiring that its steps be performed in a specific order. Accordingly, where a method claim does not specifically state in the claims or descriptions that the steps are to be limited to a specific order, it is no way intended that an order be inferred, in any respect. This holds for any possible non- express basis for interpretation, including matters of logic with respect to
arrangement of steps or operational flow, plain meaning derived from grammatical organization or punctuation, or the number or type of aspects described in the specification.
As used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.
The word "or" as used herein means any one member of a particular list and can also include any combination of members of that list.
Ranges can be expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as "about" that particular value in addition to the value itself. For example, if the value "10" is disclosed, then "about 10" is also disclosed. It is also understood
that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11 , 12, 13, and 14 are also disclosed.
As used herein, the terms "optional" or "optionally" means that the
subsequently described event or circumstance can or can not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
As used herein, the term "subject" refers to the target of administration, e.g., an animal. Thus, the subject of the herein disclosed methods can be a vertebrate, such as a mammal. The subject of the herein disclosed methods can be a human. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered. In one aspect, the subject is a patient. A patient refers to a subject afflicted with a disease or disorder, such as, for example, cancer and/or aberrant cell growth. The term "patient" includes human and veterinary subjects. In an aspect, the subject has been diagnosed with a need for treatment for an inflammatory disease. In another aspect, the subject has not yet been diagnosed and the disclosed methods to predict a higher risk for developing an inflammatory disease.
The terms "treating", "treatment", "therapy", and "therapeutic treatment' as used herein refer to curative therapy, prophylactic therapy, or preventative therapy. As used herein, the terms refers to the medical management of a subject or a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder, such as, for example, cancer or a tumor. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder. In various aspects, the term covers any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it;
(ii) inhibiting the disease, i.e., arresting its development; or (iii) relieving the disease, i.e., causing regression of the disease.
As used herein, the terms "administering" and "administration" refer to any method of providing a composition to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, intracardiac administration, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ophthalmic administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration.
Administration can be continuous or intermittent. In various aspects, a preparation can be administered therapeutically; that is, administered to treat an existing disease or condition. In further various aspects, a preparation can be administered prophylactically; that is, administered for prevention of a disease or condition.
The term "contacting" as used herein refers to bringing a disclosed composition or peptide or pharmaceutical preparation and a cell, target receptor, or other biological entity together in such a manner that the compound can affect the activity of the target (e.g., receptor, transcription factor, cell, etc.), either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another molecule, co-factor, factor, or protein on which the activity of the target is dependent.
As used herein, the terms "effective amount" and "amount effective" refer to an amount that is sufficient to achieve the desired result or to have an effect on an undesired condition. For example, in an aspect, an effective amount of the polymeric nanoparticle is an amount that kills and/or inhibits the growth of cells without causing extraneous damage to surrounding non-cancerous cells. For example, a
"therapeutically effective amount" refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed and like factors well known in the medical arts.
The term "pharmaceutically acceptable" describes a material that is not biologically or otherwise undesirable, i.e., without causing an unacceptable level of undesirable biological effects or interacting in a deleterious manner. As used herein, the term "pharmaceutically acceptable carrier" refers to sterile aqueous or
nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.
As used herein, the term "RNA silencing agent" refers to an RNA which is capable of preventing complete processing (e.g, the full translation and/or
expression) of a mRNA molecule through a post-transcriptional silencing mechanism. RNA silencing agents include small (<50 b.p.), noncoding RNA molecules, for
example RNA duplexes comprising paired strands, as well as precursor RNAs from which such small non-coding RNAs can be generated. Exemplary RNA silencing agents include siRNAs, miRNAs, and siRNA-like duplexes, as well as precursors thereof.
As used herein, the term "small interfering RNA" ("siRNA") (also referred to in the art as "short interfering RNAs") refers to an RNA (or RNA analog) comprising between about 10-50 nucleotides (or nucleotide analogs) which is capable of directing or mediating RNA interference. Preferably, an siRNA comprises between about 15-30 nucleotides or nucleotide analogs, more preferably between about 16-25 nucleotides (or nucleotide analogs), even more preferably between about 18-23 nucleotides (or nucleotide analogs), and even more preferably between about 19-22 nucleotides (or nucleotide analogs) (e.g., 19, 20, 21 or 22 nucleotides or nucleotide analogs).
As used herein, the term "microRNA" ("miRNA"), also referred to in the art as "small temporal RNAs" ("stRNAs"), refers to a small (10-50 nucleotide) RNA which is capable of directed or mediating RNA silencing. A "natural miRNA" refers to a microRNA that occurs naturally. An "miRNA disorder" shall refer to a disease or disorder characterized by a aberrant expression or activity of a natural miRNA.
As used herein, the term "RNA interference" ("RNAi") (also referred to in the art as "gene silencing" and/or "target silencing", e.g., "target mRNA silencing") refers to a selective intracellular degradation of RNA. RNAi occurs in cells naturally to remove foreign RNAs (e.g., viral RNAs). Natural RNAi proceeds via fragments cleaved from free dsRNA which direct the degradative mechanism to other similar RNA sequences. As used herein, the term "translational repression" refers to a selective inhibition of mRNA translation. Natural translational repression proceeds via miRNAs cleaved from shRNA precursors. Both RNAi and translational repression are mediated by RISC. Both RNAi and translational repression occur naturally or can be initiated by the hand of man, for example, to silence the expression of target genes.
As used herein, the term "antisense strand" of an siRNA or RNAi agent refers to a strand that is substantially complementary to a section of about 10-50 nucleotides, e.g., about 15-30, 16-25, 18-23 or 19-22 nucleotides of the mRNA of the gene targeted for silencing. The antisense strand or first strand has sequence sufficiently complementary to the desired target mRNA sequence to direct target- specific RNA interference (RNAi), e.g., complementarity sufficient to trigger the destruction of the desired target mRNA by the RNAi machinery or process (RNAi interference) or complementarity sufficient to trigger translational repression of the
desired target mRNA. The term "sense strand" or "second strand" of an siRNA or RNAi agent refers to a strand that is complementary to the antisense strand or first strand. Antisense and sense strands can also be referred to as first or second strands, the first or second strand having complementarity to the target sequence and the respective second or first strand having complementarity to said first or second strand. miRNA duplex intermediates or siRNA-like duplexes include a miRNA strand having sufficient complementarity to a section of about 10-50 nucleotides of the mRNA of the gene targeted for silencing and a miRNA* strand having sufficient complementarity to form a duplex with the miRNA strand.
As used herein, the term "guide strand" refers to a strand of an RNAi agent, e.g., an antisense strand of an siRNA duplex, that enters into the RISC complex and directs cleavage of the target mRNA.
The practice of the present invention will typically employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant nucleic acid (e.g., DNA) technology, immunology, and RNA interference (RNAi) which are within the skill of the art. Non- limiting descriptions of certain of these techniques are found in the following publications: Ausubel, R, et al., (eds.), Current Protocols in Molecular Biology, Current Protocols in Immunology, Current Protocols in Protein Science, and Current Protocols in Cell Biology, all John Wiley & Sons, N. Y, edition as of December 2008; Sambrook, Russell, and Sambrook, Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2001 ; Harlow, E. and Lane, D., Antibodies - A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1988; Freshney, R.I., "Culture of Animal Cells, A Manual of Basic Technique", 5th ed., John Wiley & Sons, Hoboken, NJ, 2005. Non-limiting information regarding therapeutic agents and human diseases is found in Goodman and
Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., McGraw Hill, 2005, Katzung, B. (ed.) Basic and Clinical Pharmacology, McGraw-Hill/Appleton & Lange; 10th ed. (2006) or 11th edition (July 2009).
As used herein, the terms "inflammatory disease" and "inflammatory disorder" refer to diseases, disorders, and conditions characterized by abnormal inflammation. Examples include type 2 diabetes and cardiovascular diseases, such as
atherosclerosis, stroke, and ischemic heart disease.
As used herein, the term "anti-inflammatory agent" refers to substance or treatment that reduce inflammation or swelling. For example, the anti-inflammatory agent can be an anti-IL6 drug, such as tocilizumab (Actemra), siltuximab (Sylvant),
Sarilumab, clazakizumab, olokizumab (CDP6038), elsilimomab, BMS- 945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ARGX-109, FE301, and FM101. The anti-inflammatory agent can be an anti-IL1 drug, such as canakinumab or rilonacept. The anti-inflammatory agent can be a nonsteroidal anti-inflammatory drug (NSAID). Examples of anti-inflammatory agents include Alclofenac,
Alclometasone Dipropionate, Algestone Acetonide, alpha Amylase, Amcinafal, Amcinafide, Amfenac Sodium, Amiprilose Hydrochloride, Anakinra, Anirolac, Anitrazafen, Apazone, Balsalazide Disodium, Bendazac, Benoxaprofen,
Benzydamine Hydrochloride, Bromelains, Broperamole, Budesonide, Carprofen, Cicloprofen, Cintazone, Cliprofen, Clobetasol Propionate, Clobetasone Butyrate,
Clopirac, Cloticasone Propionate, Cormethasone Acetate, Cortodoxone, Decanoate, Deflazacort, Delatestryl, Depo-Testosterone, Desonide, Desoximetasone,
Dexamethasone Dipropionate, Diclofenac Potassium, Diclofenac Sodium,
Diflorasone Diacetate, Diflumidone Sodium, Diflunisal, Difluprednate, Diftalone, Dimethyl Sulfoxide, Drocinonide, Endrysone, Enlimomab, Enolicam Sodium,
Epirizole, Etodolac, Etofenamate, Felbinac, Fenamole, Fenbufen, Fenclofenac, Fenclorac, Fendosal, Fenpipalone, Fentiazac, Flazalone, Fluazacort, Flufenamic Acid, Flumizole, Flunisolide Acetate, Flunixin, Flunixin Meglumine, Fluocortin Butyl, Fluorometholone Acetate, Fluquazone, Flurbiprofen, Fluretofen, Fluticasone
Propionate, Furaprofen, Furobufen, Halcinonide, Halobetasol Propionate,
Halopredone Acetate, Ibufenac, Ibuprofen, Ibuprofen Aluminum, Ibuprofen Piconol, llonidap, Indomethacin, Indomethacin Sodium, Indoprofen, Indoxole, Intrazole, Isoflupredone Acetate, Isoxepac, Isoxicam, Ketoprofen, Lofemizole Hydrochloride, Lomoxicam, Loteprednol Etabonate, Meclofenamate Sodium, Meclofenamic Acid, Meclorisone Dibutyrate, MefenamicAcid, Mesalamine, Meseclazone, Mesterolone, Methandrostenolone, Methenolone, Methenolone Acetate, Methylprednisolone Suleptanate, Momiflumate, Nabumetone, Nandrolone, Naproxen, Naproxen Sodium, Naproxol, Nimazone, Olsalazine Sodium, Orgotein, Orpanoxin, Oxandrolane, Oxaprozin, Oxyphenbutazone, Oxymetholone, Paranyline Hydrochloride, Pentosan Polysulfate Sodium, Phenbutazone Sodium Glycerate, Pirfenidone, Piroxicam,
Piroxicam Cinnamate, Piroxicam Olamine, Pirprofen, Prednazate, Prifelone, Prodolic Acid, Proquazone, Proxazole, Proxazole Citrate, Rimexolone, Romazarit, Salcolex, Salnacedin, Salsalate, Sanguinarium Chloride, Seclazone, Sermetacin, Stanozolol, Sudoxicam, Sulindac, Suprofen, Talmetacin, Talniflumate, Talosalate, Tebufelone, Tenidap, Tenidap Sodium, Tenoxicam, Tesicam, Tesimide, Testosterone, Testosterone
Blends, Tetrydamine, Tiopinac, Tixocortol Pivalate, Tolmetin, Tolmetin Sodium, Triclonide, Triflumidate, Zidometacin, Zomepirac Sodium.
Methods of Diagnosis
Gene [Expression Assay
Methods of "determining gene expression levels" include methods that quantify levels of gene transcripts as well as methods that determine whether a gene of interest is expressed at all. A measured expression level may be expressed as any quantitative value, for example, a fold-change in expression, up or down, relative to a control gene or relative to the same gene in another sample, or a log ratio of expression, or any visual representation thereof, such as, for example, a "heatmap" where a color intensity is representative of the amount of gene expression detected. Exemplary methods for detecting the level of expression of a gene include, but are not limited to, Northern blotting, dot or slot blots, reporter gene matrix, nuclease protection, RT-PCR, microarray profiling, differential display, 2D gel electrophoresis, SELDI-TOF, ICAT, enzyme assay, antibody assay, and MNAzyme-based detection methods. Optionally a gene whose level of expression is to be detected may be amplified, for example by methods that may include one or more of: polymerase chain reaction (PCR), strand displacement amplification (SDA), loop-mediated isothermal amplification (LAMP), rolling circle amplification (RCA), transcription- mediated amplification (TMA), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), or reverse transcription polymerase chain reaction (RT-PCR).
A number of suitable high throughput formats exist for evaluating expression patterns and profiles of the disclosed genes. Numerous technological platforms for performing high throughput expression analysis are known. Generally, such methods involve a logical or physical array of either the subject samples, the biomarkers, or both. Common array formats include both liquid and solid phase arrays. For example, assays employing liquid phase arrays, e.g., for hybridization of nucleic acids, binding of antibodies or other receptors to ligand, etc., can be performed in multiwell or microtiter plates. Microtiter plates with 96, 384 or 1536 wells are widely available, and even higher numbers of wells, e.g., 3456 and 9600 can be used. In general, the choice of microtiter plates is determined by the methods and equipment, e.g., robotic handling and loading systems, used for sample preparation and analysis. Exemplary systems include, e.g., xMAP® technology from Luminex (Austin, TX), the SECTOR® Imager with MULTI-ARRAY® and MULTI-SPOT® technologies from Meso Scale
Discovery (Gaithersburg, MD), the ORCA™ system from Beckman-Coulter, Inc. (Fullerton, Calif.) and the ZYMATE™ systems from Zymark Corporation (Hopkinton, MA), miRCURY LNA™ microRNA Arrays (Exiqon, Woburn, MA).
Alternatively, a variety of solid phase arrays can favorably be employed to determine expression patterns in the context of the disclosed methods, assays and kits. Exemplary formats include membrane or filter arrays (e.g., nitrocellulose, nylon), pin arrays, and bead arrays (e.g., in a liquid "slurry"). Typically, probes corresponding to nucleic acid or protein reagents that specifically interact with (e.g., hybridize to or bind to) an expression product corresponding to a member of the candidate library, are immobilized, for example by direct or indirect cross-linking, to the solid support. Essentially any solid support capable of withstanding the reagents and conditions necessary for performing the particular expression assay can be utilized. For example, functionalized glass, silicon, silicon dioxide, modified silicon, any of a variety of polymers, such as (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polystyrene, polycarbonate, or combinations thereof can all serve as the substrate for a solid phase array.
In one embodiment, the array is a "chip" composed, e.g., of one of the above- specified materials. Polynucleotide probes, e.g., RNA or DNA, such as cDNA, synthetic oligonucleotides, and the like, or binding proteins such as antibodies or antigen-binding fragments or derivatives thereof, that specifically interact with expression products of individual components of the candidate library are affixed to the chip in a logically ordered manner, i.e., in an array. In addition, any molecule with a specific affinity for either the sense or anti-sense sequence of the marker nucleotide sequence (depending on the design of the sample labeling), can be fixed to the array surface without loss of specific affinity for the marker and can be obtained and produced for array production, for example, proteins that specifically recognize the specific nucleic acid sequence of the marker, ribozymes, peptide nucleic acids (PNA), or other chemicals or molecules with specific affinity.
Microarray expression may be detected by scanning the microarray with a variety of laser or CCD-based scanners, and extracting features with numerous software packages, for example, IMAGENE™ (Biodiscovery), Feature Extraction Software (Agilent), SCANLYZE™ (Stanford Univ., Stanford, CA.), GENEPIX™ (Axon Instruments).
Methvlation Assay
There are many techniques for measuring DNA methylation. For example, one can use Methylation-Specific-Quantitative PCR (MS-QPCR) or to measure DNA
Methylation. (See: Eads C. A., MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000 Apr. 15; 28(8): E32; 2. Darst R. P., Bisulfite sequencing of DNA. Curr Protoc Mol Biol. 2010 July; Chapter 7: Unit 7.9.1-17, and Cottrell S. E., et al., A real-time PCR assay for DNA-methylation using methylation specific blockers, Nucleic Acids Res. 2004; 32(1): e10.). In some embodiments, the methylation is quantified with PyroMark™MD Pyrosequencing System (Qiagen) using PyroPyroMark® Gold Q96 Reagents (Qiagen, Cat#972804). Other approaches for methylation quantification include, for example, methylation specific QPCR or quantitative bisulfite sequencing of methylation.
ARID5B Inhibitors
Disclosed herein are ARID5B inhibitors that reduce the level of endogenous ARID5B in a subject. The term "inhibitor" refers to a compound which is capable of reducing the expression of a gene or the activity of the product of such gene to an extent sufficient to achieve a desired biological or physiological effect. Therefore, the term "inhibitor" as used herein includes one or more of an oligonucleotide inhibitor, including siRNA, shRNA, miRNA and ribozymes.
Gene Silencing
As used herein, the phrase "RNA interference" (also called "RNAi" herein) refers to its meaning as is generally accepted in the art. The term generally refers to the biological process of inhibiting, decreasing, or down-regulating gene expression in a cell, and which is mediated by short interfering nucleic acid molecules (e.g., siRNAs, miRNAs, shRNAs). Additionally, the term "RNA interference" (or "RNAi") is meant to be equivalent to other terms used to describe sequence-specific RNA interference, such as post-transcriptional gene silencing, translational inhibition, transcriptional inhibition, or epigenetics. For example, nucleic acid agents of the invention can be used to epigenetically silence ARID5B at either the post- transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic modulation of gene expression by nucleic acid agents of the invention can result from modification of chromatin structure or methylation patterns to alter gene expression. In another non-limiting example, modulation of gene expression by nucleic acid agents of the invention can result from cleavage of RNA (either coding or non-coding RNA) via RISC, or via translational inhibition, as is known in the art or modulation can result from transcriptional inhibition.
The terms "inhibit," "down-regulate," "reduce" or "knockdown" as used herein refer to their meanings as are generally accepted in the art. With reference to exemplary single-stranded RNAi molecules of the invention, the terms generally refer
to the reduction in the (i) expression of a gene or target sequence and/or the level of RNA molecules encoding one or more proteins or protein subunits, and/or (ii) the activity of one or more proteins or protein subunits, below that observed in the absence of the single-stranded RNAi molecules of the invention. Down-regulation can also be associated with post-transcriptional silencing, such as RNAi-mediated cleavage, or by alteration in DNA methylation patterns or DNA chromatin structure. Inhibition, down-regulation, reduction or knockdown with an RNAi agent can be in reference to an inactive molecule, an attenuated molecule, an RNAi agent with a scrambled sequence, or an RNAi agent with mismatches. The phrase "gene silencing" refers to a partial or complete loss-of-function through targeted inhibition of an endogenous target gene in a cell. As such, the term is used interchangeably with RNAi, "knockdown," "inhibition," "down-regulation," or "reduction" of expression of a target gene.
The nucleic acid sequence for ARID5B is known in the art, and it is within the skill of those in the art to design and produce gene silencing oligonucleotides such as siRNA using this sequence. For example, siRNA that silence ARID5B are
commercially available from ThermoFisher Scientific (e.g. Catalog No. S38579, S38580, S38581).
Targeted Methylation
The disclosed methods can involve the targeted methylation of CpG sites within the ARID5B gene. Enzymes capable of modifying methylation status are known on the art and can be targeted to ARID5B gene to methylate the CpG sites. In some embodiments, targeted DNA methylation of the CpG sites within the ARID5B gene is accomplished using a gene editing tool such as a zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), mega-nuclease, CRISPR/Cas, structure-guided endonuclease (SGN), or targetron. All of themcan achieve precise genetic modifications by inducing targeted DNA double-strand breaks (DSBs).
Depending on the cell cycle stage, as well as the presence or absenceof a repair template with homologous terminal regions, the DSB may then be repaired by either non-homologous end joining repair system (NHEJ) or homologous recombination- based double-strand break repair pathway (HDR).
In some embodiments, targeted DNA methylation of the CpG sites within the ARID5B gene is accomplished using a CRISPR system. Compositions and methods for making and using CRISPR-Cas systems are described in U.S. Pat. No.
8,697,359, which is incorporated herein in its entirety. In particular, the method can involve a catalytically inactive site specific nuclease fused to an effector domain
having methylation activity; and a guide sequence or a nucleic acid that encodes a guide sequence. In some aspects, the catalytically inactive site specific nuclease is a catalytically inactive Cas protein (e.g., a Cas9 protein or a Cpfl protein). The guide sequences may be ribonucleic acid guide sequences. In certain aspects, the guide sequence is from about 10 base pairs to about 150 base pairs in length. The one or more guide sequences may comprise two or more guide sequences.
There are various ways that a polypeptide comprising a catalytically inactive site specific nuclease fused to an effector domain having methylation or
demethylation activity can be delivered to a cell or subject, e.g., by administering a nucleic acid that encodes the polypeptide, which nucleic acid may be, e.g., a viral vector or may be a translatable nucleic acid (e.g, synthetic modified mRNA.
Examples of modified mRNA are described in Warren et al. (Cell Stem Cell 7(5):618- 30, 2010, Mandal PK, Rossi DJ. Nat Protoc. 2013 8(3):568-82, US Pat. Pub. No. 20120046346 and/or WO2011/130624.
In some aspects, one or more guide sequences include sequences that recognize DNA in a site-specific manner. For example, guide sequences can include guide ribonucleic acid (RNA) sequences utilized by a CRISPR system or sequences within a TALEN or zinc finger system that recognize DNA in a site-specific manner. The guide sequences comprise a portion that is complementary to a portion of each of the one or more genomic sequences and comprise a binding site for the catalytically inactive site specific nuclease. In some embodiments, the RNA sequence is referred to as guide RNA (gRNA) or single guide RNA (sgRNA).
In some aspects, a single RNA sequence can be complementary to one or more (e.g., all) of the genomic sequences that are being modulated or modified. In one aspect, a single RNA is complementary to a single target genomic sequence. In a particular aspect in which two or more target genomic sequences are to be modulated or modified, multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) RNA sequences are introduced wherein each RNA sequence is complementary to (specific for) one target genomic sequence. In some aspects, two or more, three or more, four or more, five or more, or six or more RNA sequences are complementary to (specific for) different parts of the same target sequence. In one aspect, two or more RNA sequences bind to different sequences of the same region of DNA. In some aspects, a single RNA sequence is complementary to at least two target or more (e.g., all) of the genomic sequences. It will also be apparent to those of skill in the art that the portion of the RNA sequence that is complementary to one or more of the genomic sequences and the portion of the RNA sequence that binds to the
catalytically inactive site specific nuclease can be introduced as a single sequence or as 2 (or more) separate sequences into a cell, zygote, embryo or nonhuman animal. In some embodiments the sequence that binds to the catalytically inactive site specific nuclease comprises a stem-loop.
In some embodiments, the RNA sequence used to modify gene expression is a modified RNA sequence comprising a 5-methylcytidine (5mC). The RNA sequence can vary in length from about 8 base pairs (bp) to about 200 bp. In some
embodiments, the RNA sequence can be about 9 to about 190 bp; about 10 to about 150 bp; about 15 to about 120 bp; about 20 to about 100 bp; about 30 to about 90 bp; about 40 to about 80 bp; about 50 to about 70 bp in length.
The portion of each genomic sequence to which each RNA sequence is complementary can also vary in size. In particular aspects, the portion of each genomic sequence to which the RNA is complementary can be about 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38 39, 40, 41, 42, 43, 44, 45, 46 47, 48, 49, 50, 51, 52, 53,54, 55,
56,57, 58, 59 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 81, 82, 83, 84, 85, 86, 87 88, 89, 90, 81, 92, 93, 94, 95, 96, 97, 98, or 100 nucleotides (contiguous nucleotides) in length. In some embodiments, each RNA sequence can be at least about 70%, 75%, 80%, 85%, 90%, 95%, 100%), etc.
identical or similar to the portion of each genomic sequence. In some embodiments, each RNA sequence is completely or partially identical or similar to each genomic sequence. For example, each RNA sequence can differ from perfect complementarity to the portion of the genomic sequence by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. nucleotides. In some embodiments, one or more RNA sequences are perfectly complementary (100%>) across at least about 10 to about 25 (e.g., about 20) nucleotides of the genomic sequence.
As described herein, the one or more RNA sequences also comprise a (one or more) binding site for a (one or more) catalytically inactive site specific nuclease. The catalytically inactive site specific nuclease may be a catalytically inactive
CRISPR associated (Cas) protein. In a particular aspect, upon hybridization of the one or more RNA sequences to the one or more genomic sequences, the
catalytically inactive site specific nuclease binds to the one or more RNA sequences. In some aspects, the method further comprises administering one or more
catalytically inactive Cas nucleic acid or protein.
A variety of CRISPR associated (Cas) genes or proteins which are known in the art can be used in the methods of the invention and the choice of Cas protein will
depend upon the particular conditions of the method. Specific examples of Cas proteins include Cas1, Cas2, Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8al, Cas8a2, Cas8b, Cas8c, Cas9, CaslO, CaslOd, CasF, CasG, CasH, Csyl, Csy2, Csy3, Csel (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxIO, Csxl6, CsaX, Csx3, Cszl, Csxl5, Csfl, Csf2, Csf3, Csf4, Cpfl, and Cul966. In a particular aspect, the Cas nucleic acid or protein used in the methods is Cas9. In some embodiments a Cas protein, e.g., a Cas9 protein, may be from any of a variety of prokaryotic species. In some embodiments a particular Cas protein, e.g., a particular Cas9 protein, may be selected to recognize a particular protospacer-adjacent motif (RAM) sequence. In certain embodiments a Cas protein, e.g., a Cas9 protein, may be obtained from a bacteria or archaea or synthesized using known methods. In certain embodiments, a Cas protein may be from a gram positive bacteria or a gram negative bacteria. In some embodiments, the Cas protein is Cpfl protein or a functional portion thereof. In some embodiments, the Cas protein is Cpfl from any bacterial species or functional portion thereof.
Disclosed herein is a catalytically inactive Cas9 protein tethered to all or a portion of methyltransferase to create a chimeric protein that can be guided to specific DNA sites by one or more RNA sequences (sgRNA) to methylate ARID5B CpG sites. DNA methylation is established by two de novo DNA methyltransferases (Dnmt3a/b), and is maintained by Dnmtl.
As will be apparent to those of skill in the art, the method can further comprise introducing other molecules or factors into the cell to facilitate methylation of the genomic sequence. An agent that enhances DNA methylation may be an inhibitor of an endogenous DNA demethylase.
Sequence-specific nucleases have been developed to increase the efficiency of gene targeting or genome editing in animal and plant systems. Among them, zinc finger nucleases (ZFNs) and transcription activator- 1 ike effector nucleases (TALENs) are the two most commonly used sequence-specific chimeric proteins. Once the ZFN or TALEN constructs are introduced into and expressed in cells, the programmable DNA binding domain can specifically bind to a corresponding sequence and guide the chimeric nuclease to make a specific DNA strand cleavage. A pair of ZFNs or TALENs can be introduced to generate double strand breaks (DSBs), which activate the DNA repair systems and significantly increase the frequency of both
nonhomologous end joining (NHEJ) and homologous recombination (HR).
These and other methods for DNA methylation editing are disclosed in WO2017090724, WO2018035495, and WO2018053035, which are incorporated by reference in its entirety for these teachings.
Pharmaceutical Compositions
The compositions disclosed can be used therapeutically in combination with a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
The disclosed compositions can be formulated in buffer solutions such as phosphate buffered saline solutions, liposomes, micellar structures, and capsids. Formulations of DsiRNA agent with cationic lipids can be used to facilitate
transfection of the DsiRNA agent into cells. For example, cationic lipids, such as lipofectin (U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (published PCT International Application WO
97/30731), can be used. Suitable lipids include Oligofectamine, Lipofectamine (Life Technologies), NC388 (Ribozyme Pharmaceuticals, Inc., Boulder, Colo.), or FuGene 6 (Roche) all of which can be used according to the manufacturer's instructions.
Such compositions typically include the nucleic acid molecule and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated into the compositions.
A pharmaceutical composition is formulated to be compatible with its intended route of administration. [Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents;
antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as
ascorbic acid or sodium bisulfite; chelating agents such as
ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline,
bacteriostatic water, Cremophor EL.TM. (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a
combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active
ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
For administration by inhalation, the compositions are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Pat. No. 6,468,798.
Systemic administration can also be by transmucosal or transdermal means.
For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
The compounds can also be administered by a method suitable for administration of nucleic acid agents, such as a DNA vaccine. These methods include gene guns, bio injectors, skin patches, micro-particle DNA vaccine technology, transdermal needle-free vaccination, intranasal delivery, and
microencapsulation.
In one embodiment, the disclosed compositions are prepared with carriers that will protect the nucleic acids against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No.
4,522,811.
As defined herein, a therapeutically effective amount of a nucleic acid molecule (i.e., an effective dosage) depends on the nucleic acid selected. For instance, if a plasmid encoding an siRNA agent is selected, single dose amounts in the range of approximately 1 pg to 1000 mg may be administered; in some embodiments, 10, 30, 100, or 1000 pg, or 10, 30, 100, or 1000 ng, or 10, 30, 100, or 1000 g, or 10, 30, 100, or 1000 mg may be administered. In some embodiments, 1- 5 g of the compositions can be administered. The compositions can be administered one from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a protein, polypeptide, or antibody can include a single treatment or, preferably, can include a series of treatments.
The nucleic acid molecules of the invention can be inserted into expression constructs, e.g., viral vectors, retroviral vectors, expression cassettes, or plasmid viral vectors, e.g., using methods known in the art, including but not limited to those described in Xia et al., (2002), supra. Expression constructs can be delivered to a subject by, for example, inhalation, orally, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al.
(1994), Proc. Natl. Acad. Sci. USA, 91, 3054-3057). The pharmaceutical preparation of the delivery vector can include the vector in an acceptable diluent, or can comprise a slow release matrix in which the delivery vehicle is imbedded. Alternatively, where the complete delivery vector can be produced intact from recombinant cells, e.g.,
retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.
The expression constructs may be constructs suitable for use in the appropriate expression system and include, but are not limited to retroviral vectors, linear expression cassettes, plasmids and viral or virally-derived vectors, as known in the art. Such expression constructs may include one or more inducible promoters, RNA Pol III promoter systems such as U6 snRNA promoters or H1 RNA polymerase III promoters, or other promoters known in the art. The constructs can include one or both strands of the siRNA. Expression constructs expressing both strands can also include loop structures linking both strands, or each strand can be separately transcribed from separate promoters within the same construct.
Suitably formulated pharmaceutical compositions of this invention can be administered by means known in the art such as by parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration. In some embodiments, the pharmaceutical compositions are administered by intravenous or intraparenteral infusion or injection.
In general, a suitable dosage unit of nucleic acid agent will be in the range of 0.001 to 0.25 milligrams per kilogram body weight of the recipient per day, or in the range of 0.01 to 20 micrograms per kilogram body weight per day, or in the range of 0.01 to 10 micrograms per kilogram body weight per day, or in the range of 0.10 to 5 micrograms per kilogram body weight per day, or in the range of 0.1 to 2.5 micrograms per kilogram body weight per day. Pharmaceutical composition comprising the nucleic acid agent can be administered once daily. However, the therapeutic agent may also be dosed in dosage units containing two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. In that case, the nucleic acid agent contained in each sub-dose must be
correspondingly smaller in order to achieve the total daily dosage unit. The dosage unit can also be compounded for a single dose over several days, e.g., using a conventional sustained release formulation which provides sustained and consistent release of the nucleic acid agent over a several day period. Sustained release formulations are well known in the art. In this embodiment, the dosage unit contains a corresponding multiple of the daily dose. Regardless of the formulation, the pharmaceutical composition must contain nucleic acid agent in a quantity sufficient to inhibit expression of the target gene in the animal or human being treated. The
nucleic acid agent can be compounded in such a way that the sum of the multiple units of dsRNA together contain a sufficient dose.
Data can be obtained from cell culture assays and animal studies to formulate a suitable dosage range for humans. The dosage of compositions of the invention lies within a range of circulating concentrations that include the ED50 (as determined by known methods) with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For a compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range of the compound that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels of dsRNA in plasma may be measured by standard methods, for example, by high performance liquid chromatography.
The pharmaceutical compositions can be included in a kit, container, pack, or dispenser together with instructions for administration.
Methods of Treatment
The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) inflammatory disease or disorders. Subjects at risk for the disease can be identified by, for example, one or a
combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the detection of or the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression. Another aspect of the invention pertains to methods of treating subjects therapeutically, i.e., altering the onset of symptoms of the disease or disorder.
With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics", as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (e.g., a patient's "drug response phenotype", or "drug response genotype"). Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment according
to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.
A number of embodiments of the invention have been described.
Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims. EXAMPLES
Example 1 : Blood Monocyte Transcriptome and Epigenome Analyses Reveal Loci Associated with Human Atherosclerosis.
Epigenomics and transcriptomics can illuminate the interplay between the genome and its environment and may provide insights into the molecular basis of complex diseases, including cardiovascular disease (CVD) (Lewis, J. & Bird, A.
FEBS Lett. 285:155-159 (1991); Bird, A.P. & Wolffe, A.P. Cell 99:451-454 (1999); Jones, P. A. & Takai, D. Science 293:1068-1070 (2001); Egger, G., et al. Nature 429:457-463 (2004); Petronis, A. Nature 465:721-727 (2010)). Epigenetic targeting also is an attractive treatment strategy for reordering dysregulated gene expression. To date, epigenome-wide studies of CVD traits are limited (Reinius, L.E., et al. PLoS One. 7:e41361 (2012)) and their interpretation is potentially complicated by use of data from mixed cell types, which may obscure cell-type specific functional mechanisms. Monocytes and their derived macrophages are key players in inflammation that contribute to the development of many chronic diseases, including atherosclerosis (Lessner, S.M., et al. Am. J. Pathol. 160:2145-2155 (2002); Osterud, B. & Bjorklid, E. Physiol Rev. 83:1069-1112 (2003); Hansson, G.K. N. Engl. J. Med. 352:1685-1695 (2005); Ley, K., et al. Arterioscler. Thromb. Vase. Biol. 31:1506-1516 (2011)).
There are blood monocyte epigenome and transcriptome signatures of several CVD risk factors, including age, obesity, and cigarette smoking (Reynolds, L.M. et al. Nat. Commun. 5:5366 (2014); Reynolds, L.M. et al. BMC Genomics 16:333 (2015); Ding, J. et al. Diabetes. 64:3464-3474 (2015); Reynolds, L.M. et al. Circ Cardiovasc. Genet 8:707-716 (2015)). In this Example, transcriptome and methylome features that are associated with atherosclerosis are identified. In addition to traditional CVD risk factors, we also integrate these findings with histone modification, DNase-seq, Hi-C (genome chromosome conformation capture), and
ChlA-PET (Chromatin Interaction Analysis by Paired-End Tag) sequencing data, and in vitro functional data in order to characterize novel molecular mechanisms of atherosclerosis. This Example discloses a role of ARID5B in atherogenesis, and an epigenetically controlled regulatory site of ARID5B expression.
Methods
Participants
The present analyses are primarily based on data collected at MESA exam 5 with concurrent analyses of purified monocyte samples of 1 ,264 randomly selected MESA participants from four MESA sites [John Hopkins University (JHU); Columbia University (CO); University of Minnesota (UMN); Wake Forest University (WFU)]. The study protocol was approved by Institutional Review Boards of the four institutions. All participants signed informed consent.
Measurement of Atherosclerosis and Prevalent CVD
All measurements in humans were obtained at MESA exam 5 unless otherwise specified. To obtain carotid artery plaque scores, readers at the UW
Atherosclerosis Imaging Research Program Laboratory adjudicated carotid plaque presence or absence, defined as a focal abnormal wall thickness (carotid IMT >1.5 mm) or a focal thickening of >50% of the surrounding IMT, as reported previously (Stein, J.H. et al. J Am Soc Echocardiogr. 21:93-111 (2008); Touboul, P.J. et al. Cerebrovasc. Dis. 23:75-80 (2007)). Presence or absence of plaque acoustic shadowing was recorded. A total plaque score (range 0-12) was calculated to describe carotid plaque burden. One point per plaque was allocated for the near and far walls of each segment (CCA, bulb, ICA) of each carotid artery that was interrogated. For carotid plaque presence, intra-reader reproducibility was excellent (per reader Kappa = 0.82-1.0, overall Kappa = 0.83, 95% confidence interval [CI] 0.70-0.96), as was inter-reader reproducibility (Kappa = 0.89; 95% CI 0.72 - 1.00) (Tattersall, M.C. et al. Stroke 45:3257-3262 (2014)). The CT Reading Center for cardiac scans in the MESA is at UCLA-Biomedical Research Institute. Coronary artery calcium (CAC) score was determined using the Agatston method, which accounts for both lesion area and calcium density using Hounsfield brightness. The re-read agreement for the CAC score (intraclass correlation coefficient = 0.99) was excellent. Prevalent CVD was defined as a past history of myocardial infarction, angina (which included definite angina and probable angina if coronary
revascularization was performed at the same time or afterwards), resuscitated cardiac arrest, or stroke.
Measurement of Covariates
Weight was measured with a Detecto Platform Balance Scale to the nearest 0.5 kg. Height was measured with a stadiometer (Accu-Hite Measure Device with level bubble) to the nearest 0.1 cm. Body-mass index (BMI) was defined as weight in kilograms divided by square of height in meters. Type II diabetes mellitus (T2D) was defined as fasting glucose≥ 7.0 mmol L 1 (> 126 mg/dL) or use of hypoglycemic medication, and impaired fasting glucose was defined as fasting glucose 5.6-6.9 mmol L 1 (100-125 mg dL 1). Plasma IL-6 was measured by ultra-sensitive ELISA (Quantikine HS Human IL-6 Immunoassay; R&D Systems, Minneapolis, MN).
Plasma C-reactive protein (CRP) was measured using the BNII nephelometer (High Sensitivity CRP; Dade Behring Inc., Deerfield, IL). Resting blood pressure was measured three times in the seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, FL). The average of the last two measurements was used in analysis. Hypertension was defined as systolic pressure greater than or equal to 140 mm Hg, diastolic pressure greater than or equal to 90 mm Hg or current use of anti-hypertensive medication. The single nucleotide polymorphisms (SNPs) data were derived from MESA Affymetrix 6.0 array genotype data (Fox, C.S. et al. PLoS. Genet. 8:e1002705 (2012)).
Blood Cell Count and Purification of CD14+ and CD4+ cells
Samples for complete blood count (CBC) with differential analysis were obtained by venipuncture and collected into tubes containing
ethylenediaminetetraacetic acid (EDTA). Total circulating white blood cell count and cell subtype counts were performed at local LabCorp. Blood was also collected in sodium heparin-containing Vacutainer CPT™ cell separation tubes (Becton
Dickinson, Rutherford, NJ) to separate peripheral blood mononuclear cells from other elements within two hours from blood draw. Subsequently, monocytes and T cells were isolated with anti-CD14 and anti-CD4 monoclonal antibody coated magnetic beads, respectively, using an autoMACS automated magnetic separation unit (Miltenyi Biotec, Bergisch Gladbach, Germany). Initially flow cytometry analysis of 18 specimens was performed, including samples from all four MESA field centers, which were found to be consistently > 90% pure.
DNA/RNA Extraction
DNA and RNA were isolated from samples simultaneously using the AllPrep DNA/RNA Mini Kit (Qiagen, Inc., Hilden, Germany). DNA and RNA QC metrics included optical density (OD) measurements, using a NanoDrop spectrophotometer and evaluation of the integrity of 18 s and 28 s ribosomal RNA using the Agilent 2100 Bioanalyzer with RNA 6000 Nano chips (Agilent Technology, Inc., Santa Clara, CA)
following manufacturer's instructions. RNA with RIN (RNA Integrity) scores > 9.0 was used for global expression microarrays. The median of RIN for our 1,264 samples was 9.9.
Global mRNA Expression Quantification
The lllumina HumanHT-12 v4 Expression BeadChip and lllumina Bead Array
Reader were used to perform the genome-wide expression analysis, as previously described (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)). This data has been deposited in the NCBI Gene Expression Omnibus and is accessible through GEO Series accession number (GSE56047).
Epigenome-wide Methylation Quantification
lllumina HumanMethylation450 BeadChips and HiScan reader were used to perform the epigenome-wide methylation analysis, as previously described (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)). This methylation data has been deposited in the NCBI Gene Expression Omnibus and is accessible through GEO Series accession number (GSE56046).
Quality Control and Pre-Processing of Microarray Data
Data pre-processing and quality control (QC) analyses were performed in R using Bioconductor packages, as previously described (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)). For both monocyte and T cell assays, we included 2% blind duplicates. Correlations among technical replicates exceeded 0.997.
Multidimensional scaling plots showed the five common control samples were highly clustered together and identified three outlier samples, which were excluded subsequently.
The lllumina HumanHT-12 v4 Expression BeadChip included >47,000 probes for >30,000 genes (with unique Entrez gene IDs). Statistical analyses excluded probes with non-detectable expression in >90% of MESA samples (using a detection p-value cut-off of 0.0001), probes overlapping repetitive elements or regions, probes with low variance across the samples (<10th percentile), or probes targeting putative and/or not well-characterized genes, i.e. gene names starting with KIAA, FI_J, HS, MGC, or LOG, 14,619 mRNA transcripts from 10,989 unique genes were included in the analyses of the presented manuscript.
The lllumina HumanMethylation450 BeadChip included probes for 485K CpG sites. Exclusion criteria included probes with "detected" methylation levels in <90% of MESA samples using a detection p-value cut-off of 0.05 and 65 control probes which assay highly-polymorphic single nucleotide polymorphisms (SNPs) rather than
DNA methylation (Pidsley, R. et al. BMC Genomics 14:293 (2013)). Methylation data for the total of 484,817 CpG sites were included in the analyses.
To estimate residual sample contamination, we generated separate enrichment scores for neutrophils, B cells, T cells, and natural killer cells as described previously (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)). Residual sample contamination was adjusted for with non-monocyte cell types in all the analyses. Although most of monocytes (80-90%) are expected to be CD14+CD16- (Wong, K.L et al. Blood 118:e16-e31 (2011)), we also adjusted for expression of the FCGR3a gene (CD16a).
RNA sequencing
A subset of 374 samples was randomly selected from the 1 ,264 MESA monocyte samples for RNA sequencing. Total RNA samples were enriched for mRNA, by depleting rRNA using the MICROBExpress kit from Ambion and following the manufacturer's instructions. Poly(A) mRNA was enriched, and lllumina compatible, strand-specific libraries were constructed using lllumina's TruSeq
Stranded mRNA HT Sample Prep Kit (lllumina, RS-122-2103). 1 of total RNA with RIN≥ 8.0 was converted into a library of stranded template molecules suitable for subsequent cluster generation and sequencing by lllumina HiSeq. The libraries generated were validated using Agilent 2100 Bioanalyzer and quantitated using Quant-iT dsDNA HS Kit (Invitrogen) and qPCR. Six individually indexed cDNA libraries were pooled and sequenced on lllumina HiSeq, resulting in an average of close to 30 million reads per sample. Libraries were clustered onto flow cells using lllumina's TruSeq PE Cluster Kit v3 (PE-401-3001) and sequenced 2X100 cycles using TruSeq SBS Kit -HS (FC-401-3001) on an lllumina HiSeq™ 2500. A total of 64 lanes were run to generate approximately 30 million 2 x 101 Paired End reads per sample. The lllumina HiSeq Control Software (HCS v2.0.12) with Real Time Analysis (RTA v1.3.61) was used to provide the management and execution of the HiSeq 2500.
lllumina sequencing runs were processed to de-multiplex samples and generate FastQ files using the lllumina provided configureBclToFastq.pl script to automate running CASAVA 1.8.4 using default parameters for removal of sequencing reads failing the chastity filter (yes) and mismatches in the barcode read (0).
Following generation of FastQ files, reads were trimmed to remove poor quality reads (or read tails) using Btrim (5 base sliding window average with Q > 15) (Kong.Y. Genomics 98:152-153 (2011)) and then trimmed to remove any adaptor sequence present in the reads using custom perl scripts (trim sequences containing 11 base
tag of adaptor, final length >40 bases). The Ensembl GRCh37 Homo Sapiens reference file, annotations and Bowtie2 indexes were downloaded from the igenomes website for mapping of the sequencing reads to the genome and read counting. Bowtie2 (2.1.0) and TopHat2 (2.0.8) were used to map the sequencing reads to the genome using a mate-inner-distance of 100 bp and 'firststrand' options
(Langmead.B., et al. Genome Biol. 10, R25 (2009); Trapnell, C, et al. Bioinformatics. 25:1105-1111 (2009)) . Following alignment, bam files were merged using the samtools (0.1.19) merge function 4, and read counts per gene were obtained using HTSeq (0.5.4p3). The 'intersection-strict' overlap resolution mode and 'stranded reverse' options were used in HTSeq.
Data pre-processing and QC analyses were performed in R using
Bioconductor packages. The transcript-based raw count data files for each sample from TopHat2 were combined into a count matrix with 56,303 features (rows) and 374 MESA samples (columns). The median total count per sample was 28.8 million. Reads denoted by TopHat2 as "no_feature","ambiguous", "too_low_aQual",
"not_aligned", "alignment_not_unique" were removed. Counts were converted to Counts Per Million (CPM) using the cpm function of the edgeR package
(Robinson,M.D., et al. Bioinformatics. 26:139-140 (2010)), and all features with CPM < 0.25 in >90% of the 374 MESA samples were removed. Features assigned to the mitochondrial genome were removed as well. Using the biomaRt package and querying the Ensembl BioMart database, Entrez Gene IDs, Gene Symbols, genome coordinates, gene length and percent GC content were obtained for 12,585 features which had a corresponding Entrez ID or lllumina HumanHT-12 v4 probe ID. To be able to continue to use the flexible and computationally efficient linear modeling functions in R, we transformed the raw count data to log counts per million (y = logCPM):
where CgS is the raw count of gene transcript g in sample s, and Ts is the normalized total count of sample s, using the Trimmed Mean of M-values (TMM) normalization method (Robinson, M.D. & Oshlack, A. Genome Biol. 11:R25 (2010)) as
implemented in the calcNormFactors function in the edgeR Bioconductor package (Robinson, M.D., et al. Bioinformatics. 26:139-140 (2010)). Ether only this TMM normalization was performed, or quantile normalization (QN) was applied to the logCPM values. Because the logCPM values' variance tends to decrease with increasing count for smaller counts, we used the voom function of the limma package to estimate the mean-variance trend non-parametrically and to predict the residual
variance of each individual observation for each gene. Then the inverse residual variances were incorporated into the linear modeling (Im) as weights in a standard manner. The same low variance filter that was used for the microarray data was imposed for the logCPM data, removing another 192 features with the lowest variance and retaining 12,380 features for analysis. Weighted linear model analyses wasWe then performed with the otherwise exact same models as for the microarray data.
Bisulfite treatment of genomic DNA and pyrosequencing
A subset of 90 samples was selected from the 1 ,264 MESA monocyte samples, based on carotid plaque score extremes, matched for age, sex, and race. Genomic DNA from monocytes was bisulfite modified using the EZ DNA
Methylation™ Kit (Zymo Research Co., Irvine, CA) according to the manufacturer's protocol for the Infinium methylation assay. Primers (F1-Biotinated 5'- GAAAATAGGAAATGTTTAATTGTG-3' (SEQ ID NO:2), R1 5'- TCACTATACTCCTAACAACCAACC-3' (SEQ ID NO:3)) for pyrosequencing assays of ARID5B-cg25953130 were designed using PSQ assay design software version 1.0.6 (Biotage, Uppsala, Sweden). PCR was performed with the PyroMark PCR Master Mix (Qiagen Inc.). Pyrosequencing was conducted using PyroMark Gold Q98 Reagents (Qiagen Inc.). Methylation values for each CpG site were calculated using Pyro Q-CpG software 1.0.9 (Biotage).
Weighted Gene Co-Expression Network Analyses
The Weighted Gene Co-Expression Network Analysis (WGCNA) method was used to construct network modules of highly correlated transcripts, using the R package WGCNA (Langfelder, P. & Horvath, S. BMC. Bioinformatics. 9:559 (2008)). A total of 1 ,261 MESA samples were included in the co-expression network analysis after removing three outlier samples based on hierarchical clustering, and 13,196 mRNA transcripts were included. First, an unsigned weighted network was constructed based on the pairwise correlations among all transcripts considered, using a soft thresholding power of 5, chosen to produce approximately a scale-free topology. Then, using the topological overlap measure to estimate the network interconnectedness, the transcripts were hierarchically clustered. The default parameters of WGCNA were used, except for changing the correlation type from Pearson to biweight midcorrelation (which is more robust to outliers), the deepSplit setting from 2 to 3, the detectCutHeight value from 0.995 to 0.999, the maximum block size from 5,000 to 14,000 transcripts, and the minimum size for module detection from 20 to 10.
WGCNA produces a set of modules, each containing a unique set of mRNA transcripts. The module eigengene was obtained to represent each module, which corresponds to the first eigenvector of the within-module expression correlation matrix (or the first right-singular vector of the standardized within-module expression matrix).
Association Analyses
The overall goal of the association analysis was to characterize the associations of each measure of atherosclerosis (carotid plaque and CAC) with each of genome-wide measures of mRNA expression and DNA methylation. Analyses were performed using the linear model (Im) function of the Stats package and the stepAIC function of the MASS package in R. Reported correlations (r) represent the partial Pearson product-moment correlation coefficient. Separate linear regression models were fit for each measure of atherosclerosis, with 1) genome-wide (log2 transformed) mRNA expression profiles, 2) network module eigengenes from
WGCNA, and 3) genome-wide DNA methylation profiles (M-values). The M-value is well suited for high-level analyses and can be transformed into the beta-value, an estimate of the percent methylation of an individual CpG site that ranges from 0 to 1 (M is logit(beta-value)). P-values were adjusted for multiple testing using the q-value FDR method (Storey, J.D. & Tibshirani, R. Proc. Natl. Acad. Sci. U. S. A 100:9440- 9445 (2003)) and Benjamini Hochberg FDR (Benjamini, Y. & Hochberg, Y. Journal of the Royal Statistical Society B 57:289-300 (2006)) when applicable. All analyses accounted for effects of residual cell contamination and covariates including age, gender, ethnicity, and study site. The full model also adjusted for traditional CVD risk factors (cigarette smoking, BMI, HDL-C and LDL-C levels, hypertension, diabetes mellitus) and statin use.
Mediation analysis
To investigate the genomic features as a potential molecular link between CVD risk factors and extent of atherosclerosis, mediation analyses was performed under an assumed causal model in which a CVD risk factor leads to a change in the genomic feature, which at least partially mediates the effects of the CVD risk factor on atherosclerotic burden. The mediation analyses accounted for the biological and technical covariates and were performed by robust Structural Equation Modeling (SEM) as implemented in the R package lavaan (Rosseel, Y. Journal of Statistical Software 48:1-36 (2012)). SEM analysis in general, and as implemented in lavaan, is based on Maximum Likelihood and the normal distribution, but provides several approaches to effectively deal with non-normal data. A first approach consists of computing robust standard errors (SE) by sandwich-type covariance matrices and
scaled test statistics, in particular the Satorra-Bentler statistic whose amount of rescaling reflects the degree of kurtosis, while the second approach uses specific bootstrapping methods to obtain both SE and test statistics (Rosseel, Y. Journal of Statistical Software 48:1-36 (2012)). The reported results are based on bootstrapping which were found to be somewhat more conservative than the use of robust SE and the Satorra-Bentler statistic.
In vivo Functional Annotation Analysis
CpGs with methylation significantly associated with carotid plaque scores or CAC were investigated for association with cis-gene expression by performing a look-up in the results from our previous analysis (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)) of the same samples. Briefly, to identify DNA methylation associated with gene expression in cis, separate linear regression models were fit with the M-value for each CpG site (adjusted for methylation chip and position effects) as a predictor of transcript expression for any autosomal gene within 1 Mb of the CpG in question. Covariates were age, sex, and race/ethnicity, and study site. mRNA expression and DNA methylation of the most significantly associated mRNA and CpGs associated with carotid plaques scores and CAC were also investigated for association with nearby genetic variants. A large window (± 1 Mb) surrounding the mRNA/CpG was investigated to avoid missing any potential effects. Covariates were age, sex, and race/ethnicity, and study site. Separate linear regression models were fit with single nucleotide polymorphisms (SNPs) located within 1 Mb as a predictor of the mRNA expression (log2 transformed) or the methylation (M-value) in the MESA samples from Caucasian participants, including SNPs with a minor allele frequency > 0.05 in the MESA Caucasian population. P- values were adjusted for multiple testing using the q-value FDR method (Storey, J.D. & Tibshirani, R. Proc. Natl. Acad. Sci. U. S. A 100:9440-9445 (2003)).
In silico Functional Annotation Analysis
For the differentially expressed co-expression modules, Ingenuity® Pathway Analysis (I PA®, QIAGEN Redwood City) was used to examine the enrichment of canonical pathways and bio-functions. In silico functional prediction of chromatin states in monocytes was performed using ChromHMM (Ernst, J. & Kellis, M. Nat Methods 9:215-216 (2012)) to predict segmentation among six states, based on histone modifications in monocyte samples from the BLUEPRINTproject (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al. Science 345:1251086 (2014)) (H3K27ac, H3K4me1, H3K4me3) and ENCODE (Rosenbloom, K.R. et al. Nucleic Acids Res. 41:D56-D63 (2013)) (H3K36me3). Other functional information
utilized includes DNase hypersensitive hotspot data in a monocyte sample
(C001UY46) from the BLUEPRINT project (Adams, D. et al. Nat Biotechnol 30:224- 226 (2012); Saeed, S. et al. Science 345:1251086 (2014)), and transcription factor binding sites detected in any cell type from ENCODE (Rosenbloom, K.R. et al.
Nucleic Acids Res. 41 :D56-D63 (2013)). Data was accessed from the UCSC
Genome Browser (Karolchik, D. et al. Nucleic Acids Res (2013)) and the Gene Expression Omnibus.
Hi-C data in a B-cell line (GM12878) (Rao, S.S. et al. Cell 159:1665-1680 (2014); Dixon, J.R. et al. Nature 485:376-380 (2012); Heidari, N. et al. Genome Res 24:1905-1917 (2014); Dixon, J.R. et al. Nature 518:331-336 (2015)), including the contact matrix heatmap and virtual 4C results were adapted from the YUE lab Hi-C Interactions and Virtual 4C website.
Functional Evaluation ofARIDSB Using in vitro Models
To examine the functional role of ARID5B, siRNA-mediated ARID5B
knockdown was used in LPS-stimulated human THP1 -monocytes. Using the protocols as described above, transcriptomic profiling was performed using the lllumina HumanHT-12 v4 Expression BeadChip, and ARID5B mRNA expression measured by qPCR.
Human monocytic THP-1 cell line was purchased from the American Tissue Culture Collection (ATCC). Cells were maintained in complete RPMI 1640 medium (Invitrogen) supplemented with 100 units ml 1 of penicillin, 100 ug ml 1 of
streptomycin, 2 mM L-glutamine, and 10% fetal bovine serum (FBS, HyClone, Logan, UT) in a humidified incubator with 5% C02 at 37 °C.
Two target-specific siRNAs for ARID5B exon 8&9 (life technologies, siRNA ID: S38579, designated as siARID5B1) and for exon 6 (siRNA ID: s38580, designated as siARIDSB 2) were used initially to compare for the knockdown efficiency. Then, the siARID5B 1 (s38579) was chosen for the remaining in vitro experiments. SiRNA transfection was performed using THP1 monocytes that were split 24h prior to transfection. 10nM of siARIDSB were electronically transfected into THP-1 cells for 24 h and 48h using Amaxa® Human Monocyte Nucleofector Kit and an Amaxa nucleofector II device (Lonza, Inc.). Scrambled siRNAs were transfected as negative controls. Samples were incubated for 24 h, followed by 3 h of LPS (LPS: 100 ng ml 1) stimulation.
Levels of cytokines in human monocytic THP-1 cells presented in Fig. 10 were measured by quantitative real-time RT-PCR using gene-specific TaqMan probe
sets in an ABI prism 7000 sequence detection system (life technologies). GAPDH mRNA was the internal loading control.
To reduce false positive rates, two independent experiments (4 siARID5B vs. 4 scrambled siRNA samples per experiment) were performed. To detect differential expression between two groups with small sample sizes, the regularized t-test implemented in the limma R package was used (Smyth, G.K. Stat. Appl. Genet. Mol. Biol. 3:Article3 (2004)). For the differentially expressed genes, Ingenuity® Pathway Analysis (I PA®, QIAGEN Redwood City) was used to examine the enrichment of canonical pathways and bio-functions.
To further interrogate the potential pro-inflammatory effect that ARI D5B may play, the third siARID5B knockdown experiment was repeated as described above and ELISA assays of culture media performed for IL-1a, the pro-inflammatory cytokine that was most significantly reduced by ARID5B mRNA Knockdown.
Supernatants collected from LPS stimulated THP1 cells were analyzed for human IL- 1a production using commercial sandwich ELISA kit (R&D Systems) according to the manufacturer's instructions. The results are representative of three or more experiments performed in triplicated as means + SEM. Levels of IL-1a mRNA expression presented in Figure 5B were measured by RT-PCR as described previously.
To further examine the effects of ARID5B knockdown on cellular functions suggested by the transcriptomic profile changes, the siARID5B knockdown experiment was repeated as described above and THP1-monoctye migration and phagocytosis assays were performed. Cell migration was evaluated using Transwell inserts (6.5 mm diameter) with polycarbonate filters (5-μιτι pore size, Corning Costar) in 24 well plates. THP1 cells (30,000 cells per well) were added to the upper chamber of the insert. The lower chamber contained 600 μΙ of RPMI 1640 medium/1% FBS with chemokine, MCP-1 (40 ng/ml). The plates were incubated at 37°C in 5% CO2 for 24 h and cells that had migrated into the lower chamber were counted using cell countess. Cell phagocytosis was evaluated using yellow-green carboxylate modified microspheres (Thermo Fisher Scientific) in 24-well plates. Cells (500,000 cells per well) were incubated with 2 μΙ of beads (beads:cells = 5:1) for 60 minutes. After thoroughly washing 10 times with cold PBS, % engulfed beads in cells were calculated using FACs.
Data Availability
Genome-wide gene expression and DNA methylation data has been deposited in the NCBI Gene Expression Omnibus (GEO) and is accessible through GEO Series accession number GSE56047 and GSE56046, respectively.
Results
Clinical Data and Sample Characteristic
The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-site, longitudinal study designed to investigate the prevalence, correlates, and progression of subclinical cardiovascular disease in a population cohort of 6,814 participants. Since its inception in 2000, five clinic visits have collected extensive clinical, socio- demographic, lifestyle, behavior, laboratory, nutrition, and medication data (Bild, D.E. et al. Am. J. Epidemiol. 156:871-881 (2002)). At Exam 5, carotid ultrasound and computed tomography (CT), were used to quantify carotid plaque burden (carotid plaque score, range 0-12) and coronary artery calcification (CAC Agatston score), respectively. These two measures of atherosclerosis burden independently predict future CVD events in MESA and other cohorts (Tattersall, M.C. et al. Stroke 45:3257- 3262 (2014); Gepner, A.D. et al. Circ. Cardiovasc. Imaging 8 (2015); Plichart, M. et al. Atherosclerosis 219:917-924 (2011); Stein, J.H., et al. J. Am. Soc. Echocardiogr. 21 :93-111 (2008)) (distribution of scores presented in Fig. 6). Table 1 shows characteristics of the MESA participants at Exam 5, overall and stratified by study site (study site 1: N=709, site 2: N=499), including demographics (age, sex, race/ethnicity, and study site), traditional CVD risk factors [cigarette smoking, body- mass index (BMI), high- and low- density lipoprotein cholesterol (HDL-C and LDL-C), hypertension, type II diabetes mellitus (T2DM)], atherosclerosis burden measures, prevalent CVD, and statin use. The transcriptome and methylome of monocytes purified at MESA Exam 5 were profiled concurrently. In a separate effort to evaluate reproducibility of single-time measures, there was a high consistency of repeated lllumina microarray data over five months (Fig. 7), suggesting both RNA expression and DNA methylation at most loci can be stable over time in an individual.
Blood Leukocyte Count and Atherosclerosis
Total white blood cell (WBC) count and its constituent subtypes were measured for all samples prior to monocyte purification, which provided the absolute monocyte count. Higher monocyte count, but not monocyte percentage or other leukocyte count, was marginally associated with carotid plaque score and CAC
[natural log (carotid plaque score/CAC + 1), p=0.026 with 0.4% of variability explained, and p=0.079, respectively], in agreement with previous reports (Madjid, M., et al. J Am Coll Cardiol. 44:1945-1956 (2004)). Positive immunoselection
(magnetic beads) (Lyons, P.A. et al. Genomics 8:64 (2007)) were used to produce samples of monocytes with greater than 90% purity. Residual contamination with neutrophils, B cells, T cells, and natural killer cells was estimated as previously reported (Liu, Y. et al. Hum Mol Genet 22:5065-5074 (2013)). Likewise, the generally small percentage of CD14+ monocytes that are also CD16+ (~10%) (Wong, K.L. et al. Blood 118:e16-e31 (2011)) was estimated based on expression of FCGR3a
(CD16a). Neither the surrogates of residual cell contamination nor the % of
CD14+CD16+ cells was associated with the measures of atherosclerosis.
Transcriptome Signature of Atherosclerosis
Transcriptomic studies of atherosclerosis in mouse models and in humans (Berisha, S.Z., et al. PLoS. One. 8:e65003 (2013); Maiwald, S., et al. Curr. Opin. Clin. Nutr. Metab Care 16:411-417 (2013); Sivapalaratnam, S. et al. PLoS. One. 7:e32166 (2012)) have been reported. However, no consensus atherosclerosis biomarkers or pathways have been identified. Of the 10,989 unique genes with RNA expression detectable in monocytes, genes were identified with expression associated with carotid plaque score (n=2) and CAC (n=13) at a q-value-based false discovery rate (FDR) (Storey, J.D. & Tibshirani, R. Proc. Natl. Acad. Sci. U. S. A 100:9440-9445 (2003)) of 0.05 after adjusting for demographics (Figure 1A and 1 B). Using the FDR level of 0.05 for the genome-wide search, signals with small effect size would inevitably be missed due to the limited statistical power for the sample size we have, thus additional signals for FDR of 0.20 were shown in Table 2 (21 gene transcripts with carotid plaque, and 104 gene transcripts with CAC). Expression of two genes, ARID5B and PDLIM7 (PDZ and LIM domain protein 7), were positively associated with both measures of atherosclerosis (FDR≤0.05); ARID5B was most significantly associated with carotid plaque score (p=6.30x10"8, FDR=1.08x10"3; with CAC: p=2.47x10"5, FDR=0.03). ARID5B plays a key metabolic role in adipose, liver and smooth muscle, and was previously implicated in lipid metabolism and adipogenesis in mice (Whitson, R.H., et al. Biochem. Biophys. Res Commun.
312:997-1004 (2003); Yamakawa, T., et al. Mol Endocrinol. 22:441-453 (2008)).
PDLIM7 is an actin and protein kinase adaptor that promotes mineralization, which might be relevant to plaques with calcium. The most significant signal associated with CAC was lower expression of CACNA2D3 (Calcium Channel, Voltage- Dependent, Alpha 2/Delta Subunit 3; p=2.08x10'8, FDR=3.19x104; with carotid plaque:
p=6.71x10"3, FDR=0.40) a tumor suppressor gene that can induce mitochondrial- mediated apoptosis (Wong, A.M. et al. Int J Cancer. 133:2284-2295 (2013)).
Additionally adjusting for other traditional CVD risk factors and statin use (in a model designated as the full model) had minimal impact on the significant associations (Figures 1C and 1 D). All of these associations had a consistent direction of effect across the independent study sites, particularly for three genes (ARID5B, TSPYL1, and ADM) which were cross-validated (p<0.05, Figures 1C and 1D). Race/ethnicity- and sex-specific analyses also were consistent across various strata (Table 3). For the top signal, ARID5B, the associations with carotid plaque were consistent in direction and nominally significant across subgroups of age (< or > 65 years), sex, and statin use (Figure 1E). Results utilizing RNA-sequencing derived expression levels from a subset (N=354) of the monocyte samples validated significant
associations between ARID5B and CAC (beta ± SE = 0.45 ± 0.20, p = 0.03) and carotid plaque (beta ± SE = 0.13 ± 0.06, p = 0.04).
To identify network modules of highly correlated transcripts in an unbiased fashion, the weighted gene co-expression network analysis was applied (Langfelder, P. & Horvath, S. BMC. Bioinformatics. 9:559 (2008)), identifying 40 co-expressed gene network modules. Three modules significantly (FDR≤ 0.05) associated with CAC (Table 4), including a cholesterol metabolism transcriptional network (CMTN) with 12 functionally coupled genes that was also associated with carotid plaque. The CMTN eigengene (the first principal component) of CMTN is associated with a transcriptional profile expected to increase intracellular cholesterol, including up- regulation of cholesterol uptake (LDLR and MYLIP) and cholesterol and fatty acid synthesis genes (HMGCS1, FDFT1, SQLE, CYP51A1, SC4MOL, SC5DL, SCD and FADS1), as well as down-regulation of cholesterol efflux genes (ABCG1 and
ABCA1). The CMTN is a signature feature of obesity, which was associated with CAC (p=3.34x10'4) (Ding, J. et al. Diabetes. 64:3464-3474 (2015)). Here, it is further showed that the CMTN was positively associated with carotid plaque (p=2.31x10-4; FDR=0.009). Among the CMTN members, LDLR expression was most significantly associated with CAC (p=1.34x10-4, FDR=0.10) and ABCG1 expression was most significantly associated with carotid plaque (p=1.48x104, FDR=0.18, Table 2). The other two network modules significantly (FDR<0.05) associated with CAC were enriched with genes involved in phagosome formation (module 39; FDR=1.32x102) and migration of cells (module 23; FDR=3.96x102; Table 4).
Methylome Signature of Atherosclerosis
Of the 484,817 CpG sites, 31 and 7 had methylation significantly associated with carotid plaque and CAC, respectively, including one CpG (cg23661483 in exon of ILVBL) associated with both carotid plaque and CAC (FDR≤ 0.05, adjusting for demographics, Figure 2A and 2B, and Table 5 showing additional signals for FDR≤ 0.10). The most significant CpG (cg06126421) associated with carotid plaque score (p=2.00x10"10, FDR=8.91x105) is an intergenic CpG, which recently was reported as one of the most significant smoking-associated methylation sites genome-wide (Shenker, N.S. et al. Hum Mol Genet 22:843-851 (2013)). Notably, the carotid plaque-associated methylation sites include one CpG in ARID5B (cg25953130, intron 2, p=4.31x10"7, FDR=0.01), which tends to be hypomethylated in the individuals with higher carotid plaque scores. Similar results were found between cg25953130 methylation and CAC (p=6.80x10"5, FDR=0.32).
The 37 differentially methylated sites associated with carotid plaque or CAC presented higher variable CpG methylation levels (across MESA population) with the interdecile range (IDR) of the percentage of methylation (measured by beta- value (Du, P. et al. BMC Bioinformatics. 11:587 (2010)) ranging from 4 to 24% (median: 10%), compared to the whole methylome (median: 4%). The majority of the methylation sites associated with carotid plaque or CAC had inverse associations with the atherosclerosis measures (Table 5). The 37 atherosclerosis-associated CpGs are distributed among 30 unique genomic loci.
Additional adjustments in the full model had minimal impact on the significant associations, which were also consistent across the two study sites for the majority (61%) of differentially methylated sites (p<0.05, as shown for each unique loci in Figures 2C and 2D). Race/ethnicity- and sex-specific analyses also showed high consistency across the various strata (Table 6), suggesting shared effects across ancestries. At the genome-wide level, race/ethnicity-specific analyses did not uncover additional significant associations. The associations of ARID5B methylation (cg25953130, intron) with carotid plaque were consistent in direction and nominally significant across subgroups of age (< or >65 years), sex, CVD status, and statin use (Figure 2E). Pyrosequencing derived methylation of cg25953130 from a subset (n=90) of the monocyte samples significantly correlated with microarray-based methylation levels (r = 0.92, p=5.2x10"37), and validated significant associations between cg25953130 methylation and carotid plaque (beta ± se = -0.07 ± 0.03, p=6.31x10"3).
In Vivo and In Silico Functional Validation
DNA methylation has been viewed as an important potential regulator of gene expression (Jones, P.A. Nat Rev Genet 13:484-492 (2012)). To prioritize the list of differentially methylated CpGs, expression-associated methylation sites (eMS) reported in the same monocyte samples from a previous study were assessed (Wong, K.L et al. Blood 118:e16-e31 (2011)). Five atherosclerosis-associated CpGs whose methylation was significantly related to mRNA expression of at least one nearby gene (Table 7) was identified. Out of the five-atherosclerosis associated eMS, four had methylation correlated with mRNA expression profiles that were nominally (p<0.05) associated with atherosclerosis, including expression of SC4MOL. The CpG most significantly associated with CAC (cg05119988, located in the 5' UTR region of SC4MOL) significantly correlated (r=-0.17, p=1.2x10"10, FDR=7.3x108) with mRNA expression of SC4MOL, a member of the identified CMNT, which was nominally associated with both carotid plaque and CAC. The SC4MOL eMS resides in a
predicted weak promoter region of a B cell line; however, this region was identified as heterochromatin in monocytes (using ChromHMM (Ernst, J. & Kellis, M. Nat Methods 9:215-216 (2012)) for histone modification data from BLUEPRINT (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al. Science 345:1251086 (2014)), Fig. 8, Table 5 and Table 7).
The ARID5B CpG (cg25953130) was the only CpG site significantly associated with expression of ARID5B (p=3.84x10'14, FDR=5.70x106; Figure 3A). As shown in Figure 3B, it overlaps a DNase hypersensitive hotspot (BLUEPRINT monocyte data (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al. Science 345:1251086 (2014))), a predicted strong enhancer (using both monocyte and B cell line histone mark data from the BLUEPRINT (Adams, D. et al. Nat Biotechnol 30:224-226 (2012); Saeed, S. et al. Science 345:1251086 (2014)) and ENCODE (Rosenbloom, K.R. et al. Nucleic Acids Res. 41:D56-D63 (2013)) projects, respectively), and a transcription factor binding site occupied by EP300 (in a neuroblastoma cell line). More importantly, chromatin-capture sequencing
technologies (both Hi-C and ChlA-PET) confirmed direct interactions between regions in the ARID5B cg25953130 locus and the ARID5B promoter region in B cell line (Rao, S.S. et al. Cell 159:1665-1680 (2014); Dixon, J.R. et al. Nature 485:376- 380 (2012); Heidari, N. et al. Genome Res 24, 1905-1917 (2014); Dixon, J.R. et al. Nature 518:331-336 (2015)) (Figure 3C). These data, together with the publically available functional data, strongly support the presence of an ARID5B regulatory region in the ARID5B gene body flanking ARID5B cg25953130.
To test whether the assumed methylation effects on atherosclerosis burden were mediated through its associated mRNA expression, Structural Equation
Modeling was used with bootstrapping (SEM, R package lavaan (Rosseel, Y. Journal of Statistical Software 48:1-36 (2012))) to perform mediation analyses. ARID5B mRNA expression significantly mediated 15% and 14% of the total effect of this ARID5B CpG on carotid plaque score (indirect effect, p=2.1x10-4) and CAC (p=2.1 x103), respectively.
The inverse association between methylation of this ARID5B CpG and carotid plaque score after adjusting for ARID5B expression (direct effect) was also significant. Jointly, the associations of ARID5B gene expression and methylation levels with atherosclerosis explain an additional 2.3% of the variability in carotid plaque score beyond well-known CVD risk factors and statin use. The effect sizes of ARID5B gene expression and methylation levels associating with carotid plaque score are higher than the effect sizes of T2DM (1 % of variability) or hypertension
(0.9%) in the same model. These data suggest that different types of related genomic features (mRNA expression and DNA methylation) may offer additive values in prediction of CVD susceptibility.
To further demonstrate the clinical relevance of ARID5B, the tertiles of ARID5B mRNA expression and ARID5B cg25953130 methylation were associated with presence of carotid plaque (defined as carotid plaque score greater than zero, N=816 cases), presence of CAC (defined as CAC greater than zero, N=844 cases), and prevalent CVD (history of a coronary heart event or stroke, N=64 cases).
ARID5B mRNA expression was positively associated with presence of carotid plaque (3rd fertile odds ratio=2.10, 95% CI: 1.42-3.09, p=1.87x10"4), presence of CAC (3rd tertile odds ratio=2.10, 95% CI: 1.42-3.09, p=1.87x104), and prevalent CVD (3"1 fertile odds ratio=2.33, 95% CI: 1.08-5.02, p=3.12x10"2, Figure 4A); while ARID5B cg25953130 methylation was inversely associated with presence of carotid plaque (3rd tertile odds ratio=0.64, 95% CI: 0.45-0.92, p= 1.59x10 ) and presence of CAC (3ri tertile odds ratio=0.64, 95% CI: 0.45-0.92, p=1.59x10"2, Figure 4B) in the full model. To examine the dose response relationship between ARID5B and extent of atherosclerosis, which may indicate their potential contribution to the progression of plaques, we performed linear regression analysis while excluding those with zero value of carotid plaque score. The associations with carotid plaque score remain significant for the ARID5B mRNA expression (unique variability explained: 1.2%, p=1.1x103) and cg25953130 methylation (unique variability explained: 0.73%, p=1.1x10"2).
Identified Genomic Features and Known CVD Risk Factors
Among the atherosclerosis-associated genomic features, eight mRNA (Table 8) and 33 CpGs (Table 9) were also associated with one or more traditional CVD risk factors, particularly demographics (age, sex, race/ethnicity), cigarette smoking, and obesity. For three mRNA and 29 CpGs (bolded in Table 6 and Table 9), the predicted effects of the majority of CVD risk factors on atherosclerosis that were mediated through the genomic features have the similar direction as the observed associations between the CVD risk factors and the measure of atherosclerosis.
ARID5B expression was positively associated with many CVD risk factors (FDR<0.05 with adjustment for demographic variables), such as age, (p=2.06x10" 13), BMI (p=1.67x10"8), T2DM (p=3.43x10"5), and inflammatory stress (measured by plasma interleukin-6 levels (IL6; p=1.36x10"10), and inversely associated with HDL-C levels (p=6.86x10"6). ARID5B methylation (cg25953130) was associated inversely with age (p=3.33 x10"11) and plasma IL-6 levels (p=0.004), and the ARID5B
CpG tended to be hypomethylated in current smokers (p=7.19x107). \f ARID5B is in fact causal, mediation analyses showed the expression of ARID5B significantly mediated 10% and 25% of the total effect of age and IL-6 on carotid plaque score (p=7.46x10"6, 4.33x10"5, respectively), and the ARID5B methylation significantly mediated 7% and 10% of the total effect of age and IL6 on carotid plaque score (p=2.57x10"4, 8.28 x103, respectively).
ARID5B RNA Expression and Methylation in CD4+ T cells
To examine the ARID5B expression and methylation across cell-types, similar analyses were performed in a subset of 517 MESA CD4+ T cell samples.
Correlations for ARID5B expression and methylation between monocyte and T cells were weak (r=0.12, 0.30, respectively). Within T cell samples, ARID5B expression was inversely correlated with cg25953130 methylation (r = -0.45, p = 1.27x10"31), as seen in monocytes. The ARID5B mRNA and cg25953130 methylation associations with carotid plaque and CAC were not significant in T cell samples (p>0.05), but remained statistically significant (p ranges from 3.8x103 to 7.2x103) when analyzed in the monocyte samples from the same subset. In the same data, however, there was an association of AHRR cg05575921 with carotid plaque score and CAC score in T cell samples (p=3.18x105, 5.89x10"5, respectively), with a strong correlation between the two cell types for the AHRR methylation site (r=0.97). AHRR
hypomethylation is a well-known, robust biomarker of smoking that is linked to carotid plaque score in MESA (Reynolds, L.M. et al. Circ Cardiovasc. Genet 8:707-716 (2015)). These results demonstrate examples of both potential cell-type specific and shared genomic features in relation to burden of atherosclerosis.
Functional Evaluation ofARID5B Using In Vitro Models
Although little is known about the majority of identified genomic features, pleotropic effects of ARID5B in adipogenesis (Whitson, R.H., et al. Biochem.
Biophys. Res Commun. 312:997-1004 (2003)), chondrogenesis (Hata, K. et al. Nat Commun. 4:2850. (2013)), autoimmune diseases (Yang, W. et al. Am J Hum Genet. 92:41-51 (2013); Okada, Y. et al. Nat Genet. 44:511-516 (2012)), lipid metabolism (Yamakawa, T., et al. Mol Endocrinol. 22:441-453 (2008)), and smooth muscle cell differentiation (Watanabe, M. et al. Circ Res. 91:382-389 (2002)) have been previously reported. As a transcription coactivator that is part of the H3K9me2 demethylase complex with PHD finger protein 2 (PHDF2), ARID5B is expected to activate its target genes by removing the repressive H3K9Me2 histone mark
(demethylation of H3K9me2) from the promoter region of target genes (Hata, K. et al. Nat Commun. 4:2850. (2013); Baba, A. et al. Nat Cell Biol. 13:668-675 (2011)). To
evaluate the functional role of ARID5B in monocytes/macrophages, the effects of its knockdown on transcriptomic profiles we was in LPS stimulated human THP1- monocytes in two independent experiments (LPS: 100 ng ml 1, n=4 per group at each experiment).
ARID5B mRNA knockdown efficiency was 85% and 76% in the two experiments (Fig. 9); both consistently showed that ARID5B knockdown decreased expression of 1,320 genes and increased expression of 1 ,162 genes (FDR<0.005 in the discovery set and FDR<0.05 in the replication set).The 2,482 ARID5B-modified genes displayed a significant overrepresentation of related pathways including inflammatory/immune response, chemotaxis, migration, extravasation signaling, and phagocytosis, and also the lipid synthesis functional pathway, compared to the background list of genes detectable on the array (enrichment FDR<0.05, Figure 5A, full list of genes provided in Table 10). Enriched bio-functions and canonical pathways in the inflammatory response pathway consisted of mainly down-regulated genes, including key proinflammatory cytokines (e.g. TNF, IL1a), activator and effector cytokines from the type I interferon signaling pathway (e.g. IRF3, IFNB1 , STAT1 and STAT2), and antigen processing and presentation genes (e.g. HC class II cell surface receptors: HLA-DRA, and HLA-DRBs, Fig. 9, bolded in Table 10), collectively indicating decreased pathway activation. Decreased expression of genes in two of the enriched pathways, phagocytosis and lipid synthesis (Table 10), overlapped with the members of two atherosclerosis-associated networks we identified in MESA (CMTN and module 39 - enriched for the phagosome formation pathway, Table 4), which suggests ARID5B may contribute to the gene network associations with atherosclerosis.
To interrogate the potential pro-inflammatory role that ARID5B may play, the third ARID5B knockdown experiment was repeated and ELISA assays of culture media performed for IL1A, the pro-inflammatory cytokine that was most significantly reduced by ARID5B mRNA knockdown (FDR: 3.79x10"8, 4.48x10-4 in the first two experiments). ARID5B knockdown decreased levels of both IL1A mRNA (p=0.02) in the THP1 -monocytes and IL1A protein expression (p=4.28x10-4) in their culture media, as shown in Figure 5B.
To further examine the effects of ARID5B knockdown on cellular functions suggested by the transcriptomic profile changes, THP1-monoctye migration and phagocytosis assays were performed. ARID5B knockdown suppressed monocyte migration (p=3x107, 0.004 in experiment 1 and 2, respectively, Figure 5C). ARID5B
knockdown also moderately inhibited monocyte phagocytosis (p=0.008) as shown in Figure 5C.
Using the data reported in the Example 1, Figure 11A gives the odds ratio of type II diabetes (T2DM) according to ARID5B levels after prior stratification of persons according to their overweigh and obesity status, the strongest risk factor for T2DM. Tertiles of ARID5B were used in these analyses to ensure an adequate representation of ARID5B levels for all strata under investigation. The ARID5B tertiles showed a strong effect in overweight and obesity subgroups, subjects with diabetes more frequently had ARID5B values in the medium and highest tertile (Odds ratio for obese subjects with the highest tertile of ARID5B was 11 , compared to those with normal weight and the lowest tertile of ARID5B, p values: 1.1 E-6)
Figure 11 B showed the mean carotid plaque scores (log transformed) according to ARID5B levels after prior stratification of persons according to their impaired glucose tolerance and diabetes status, one of the strongest risk factors for atherosclerotic CVD. The ARID5B tertiles showed a significant (p< 0.001) effect at normal, impaired glucose tolerance, and diabetes subgroups).
In conclusion, the type II diabetes and atherosclerosis risk increases with the higher levels of ARID5B in all the low, medium, and high risk groups. ARID5B significantly improves the risk stratifications for both T2DM and atherosclerosis, above and beyond their known risk factors.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
1. A method, comprising obtaining a sample from a subject having or suspected of having an inflammatory disease, and assaying the sample for methylation of an ARID5B CpG site affecting ARID5B gene expression.
2. The method of claim 1, wherein the CpG methylation site comprises a CpG site found in the nucleic acid sequence (SEQ ID NO:1).
3. The method of claim 2, wherein the CpG methylation site comprises cg25953130.
4. A method for diagnosing or prognosing an inflammatory disease in a subject, comprising assaying a sample from the subject for ARID5B expression levels, wherein detection of elevated ARID5B expression levels compared to a control is an indication that the subject has an inflammatory disease.
5. The method of claim 4, wherein the ARID5B expression levels are assayed by assaying for methylation of an ARID5B CpG site that negatively correlates with ARID5B gene expression.
6. The method of claim 5, wherein the CpG methylation site is found in the nucleic acid sequence SEQ ID NO:1.
7. The method of claim 6, wherein the CpG methylation site comprises cg25953130.
8. The method of any one of claims 4 to 6, wherein the inflammatory disease is diabetes mellitus type 2 or a cardiovascular disease.
9. The method of claim 8, wherein the cardiovascular disease comprises atherosclerosis.
10. A method for treating an inflammatory disease in a subject, comprising
obtaining a sample from a subject having or suspected of having an inflammatory disease,
assaying the sample for ARID5B expression levels, and
treating the subject for an inflammatory disease if the ARID5B expression levels are elevated compared to a control.
11. The method of claim 10, wherein the ARID5B expression levels are assayed by assaying for methylation of an ARID5B CpG site that negatively correlates with ARID5B gene expression.
12. The method of claim 11, wherein the CpG methylation site is found in the nucleic acid sequence SEQ ID NO:1.
13. The method of claim 12, wherein the CpG methylation site comprises cg25953130.
14. The method of any one of claims 10 to 13, wherein the subject is at high risk for cardiovascular disease, wherein the subject is treated for cardiovascular diseasef ARID5B expression levels are elevated.
15. The method of any one of claims 10 to 13, wherein the subject is at high risk for diabetes mellitus type 2, wherein the subject is treated for diabetes if ARID5B expression levels are elevated.
16. The method of claim 14 or 15, wherein the subject is treated with an antiinflammatory agent \f ARID5B expression levels are elevated.
17. A method for treating a subject with an inflammatory disease, comprising administering to the subject a composition comprising an ARID5B inhibitor in an amount effective to reduce endogenous expression levels of ARID5B in the subject.
18. The method of claim 17, wherein the ARID5B inhibitor is a gene silencing agent.
19. The method of claim 18, wherein the gene silencing agent comprises an antisense oligonucleotide, siRNA, or shRNA.
20. The method of claim 17, wherein the ARID5B inhibitor is a CRISPR-Cas system that methylates an ARID5B CpG site that negatively correlates with ARID5B gene expression.
21. The method of claim 20, wherein the CpG methylation site is found in the nucleic acid sequence SEQ ID NO:1.
22. The method of claim 21, wherein the CpG methylation site comprises cg25953130.
23. The method of any one of claims 17 to 22, wherein the inflammatory disease is diabetes mellitus type 2 or a cardiovascular disease.
24. The method of claim 23, wherein the cardiovascular disease comprises atherosclerosis.
25. The method of any one of claims 17 to 24, wherein prior to treatment the method further comprises detecting elevated ARID5B expression levels in a sample from the subject.
26. The method of claim 25, wherein the ARID5B expression levels are detected by assaying for methylation of an ARID5B CpG site that negatively correlates with ARID5B gene expression.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762488320P | 2017-04-21 | 2017-04-21 | |
US62/488,320 | 2017-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018195522A1 true WO2018195522A1 (en) | 2018-10-25 |
Family
ID=63856419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/028747 WO2018195522A1 (en) | 2017-04-21 | 2018-04-21 | Arid5b overexpression in inflammatory diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018195522A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182586A1 (en) * | 2000-12-22 | 2002-12-05 | Morris David W. | Novel compositions and methods for cancer |
US20090130096A1 (en) * | 2007-05-02 | 2009-05-21 | Siemens Medical Solutions Usa, Inc. | Gene Signature of Early Hypoxia to Predict Patient Survival |
WO2014036314A2 (en) * | 2012-08-31 | 2014-03-06 | Ignyta, Inc. | Diagnosis of rheumatoid arthritis (ra) using differentially methylated loci identified in peripheral blood mononuclear cells, t-cells, b-cells and monocytes |
WO2015124921A1 (en) * | 2014-02-19 | 2015-08-27 | The University Court Of The University Of Edinburgh | Methods and uses for determining the presence of inflammatory bowel disease |
WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016105535A2 (en) * | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway |
-
2018
- 2018-04-21 WO PCT/US2018/028747 patent/WO2018195522A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020182586A1 (en) * | 2000-12-22 | 2002-12-05 | Morris David W. | Novel compositions and methods for cancer |
US20090130096A1 (en) * | 2007-05-02 | 2009-05-21 | Siemens Medical Solutions Usa, Inc. | Gene Signature of Early Hypoxia to Predict Patient Survival |
WO2014036314A2 (en) * | 2012-08-31 | 2014-03-06 | Ignyta, Inc. | Diagnosis of rheumatoid arthritis (ra) using differentially methylated loci identified in peripheral blood mononuclear cells, t-cells, b-cells and monocytes |
WO2015124921A1 (en) * | 2014-02-19 | 2015-08-27 | The University Court Of The University Of Edinburgh | Methods and uses for determining the presence of inflammatory bowel disease |
WO2016049024A2 (en) * | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
WO2016105535A2 (en) * | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway |
Non-Patent Citations (3)
Title |
---|
LIU, Y ET AL. ET AL.: "Blood monocyte transcriptome and epigenome analyses reveal loci associated with human Atherosclerosis", NATURE COMMUNICATIONS, vol. 8, no. 1, 30 August 2017 (2017-08-30), pages 1 - 12, XP055550825 * |
LIU, Y ET AL. ET AL.: "Transcriptomics and Methylomics of Atherosclerosis in Circulating Monocytes - the Multi-Ethnic Study of Atherosclerosis. Abstract 53", CIRCULATION, vol. 131, no. 1, 10 March 2015 (2015-03-10), pages 1 * |
REYNOLDS, LM ET AL.: "Age-related variations in the methylome associated with gene expression in human monocytes and T cells", NATURE COMMUNICATIONS, vol. 5, 18 November 2014 (2014-11-18), pages 1 - 8, XP055428472 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martínez et al. | miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea | |
EP3068783B1 (en) | Agonists of hypocretin receptor 2 for use for treating heart failure | |
Dumitriu et al. | Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study | |
EP2627349B1 (en) | Obesity-related genes and their proteins and uses thereof | |
Bogner et al. | miR‐34a is upregulated in AIP‐mutated somatotropinomas and promotes octreotide resistance | |
Esposito et al. | A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity | |
US10787709B2 (en) | Methods for diagnosing risk of renal allograft fibrosis and rejection | |
US20160160217A1 (en) | Compositions and methods for characterizing and treating muscular dystrophy | |
Bayoumi et al. | Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the fibroblast growth factor 21 locus | |
Fang et al. | Caffeine exposure alters cardiac gene expression in embryonic cardiomyocytes | |
EP3144395B1 (en) | Microrna signature as an indicator of the risk of early recurrence in patients with breast cancer | |
US20150031742A1 (en) | Treatment of uterine leiomyomata | |
CN116474100B (en) | Biological target PTN related to liver cirrhosis or liver fibrosis progress to liver cancer of hepatitis B virus and application thereof | |
Chen et al. | mm9_circ_014683 regulates microglia polarization through canonical NFκB signaling pathway in diabetic retinopathy | |
JP2015508282A (en) | Materials and methods for NSAID chemoprevention in colorectal cancer | |
CN110396544A (en) | Application of CUL7 in Diagnosis, Treatment and Prognosis of Glioma | |
WO2018195522A1 (en) | Arid5b overexpression in inflammatory diseases | |
EP3983544A1 (en) | Treatment and prevention of disease mediated by wwp2 | |
WO2015086913A1 (en) | Methods for detection of the risk of obesity, the metabolic syndrome and diabetes | |
WO2010084668A1 (en) | Diagnostic method for nephrotic syndrome, prophylactic or therapeutic agent for nephrotic syndrome, and method for screening the prophylactic or therapeutic agent | |
CN116855608B (en) | Application of CITED1 in lung cancer diagnosis, treatment and prognosis prediction | |
EP4541908A1 (en) | Composition for prevention or treatment of osteoarthritis and use thereof | |
JP2011004619A (en) | Method for examining immunological disease, and method for screening medicine for preventing or treating immunological disease | |
US20220291231A1 (en) | Compositions and methods for predicting lung function decline in idiopathic pulmonary fibrosis | |
Ren et al. | Diagnostic significance of LncRNA MIAT in periodontitis and the molecular mechanisms influencing periodontal ligament fibroblasts via the miR-204-5p/DKK1 axis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18788630 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18788630 Country of ref document: EP Kind code of ref document: A1 |